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Abstract 
Substance Use Experiences and Hepatitis C Treatment Decision-Making Among 
HIV/HCV Co-infected Adults 
2007 
Lisa Marie Fink Ogawa, BS, University of Texas Health Science Center, San Antonio  
MS, University of Massachusetts, Worcester 
PhD, University of Massachusetts, Worcester 
Directed by Dr. Carol Bova 
Hepatitis C virus (HCV) infection affects between 150,000 to 300,000 human 
immunodeficiency (HIV) positive adults in the US (Alter et al., 1999; Sherman, Rouster, 
Chung, & Rajicic, 2002). The majority of co-infected adults (50%-90%) have acquired 
HCV through substance abuse (Centers for Disease Control [CDC], 1998; CDC, 2006b). 
A patient’s decision to begin HCV treatment is not straightforward. HCV evaluation and 
treatment involves a significant amount of time, energy, effort, and compliance on the 
part of the patient. There is limited information on how adults with HCV mono-infection 
make decisions about HCV evaluation and treatment (Fraenkel, McGraw, 
Wongcharatraee, & Garcia-Tsao, 2005). Even less is known about how adults with 
HIV/HCV co-infection with a history of substance abuse make treatment decisions. The 
purpose of this study was to describe substance abuse experiences and to explore how 
these related to patient decision-making about HCV treatment in HIV/HCV co-infected 
adults. Qualitative descriptive design and secondary data analysis were used to study 
these phenomena. Data were managed by using NVivo software and analyzed by 
secondary data analysis and qualitative content analysis. 
xi 
Five major themes with sub-themes emerged during the data analysis. They were: 
(1) The Evolution of Substance Abuse (with sub-themes: substance abuse initiation, 
escalation, polysubstance abuse, normalcy: a family of addicts, the enemy within, and 
transmission and disclosure), (2) Revolving Door: Going Back Out (with sub-themes: 
specific events as a trigger, emotions as a trigger, alcohol as a trigger, and destructive 
relationships as a trigger), and (3) Reconstructing Life (with sub-themes: defining 
moments in substance abuse addiction and maintaining sobriety), (4) HCV Infection 
Treatment Issues (with sub-themes: HCV treatment: not a priority, fear, and 
misinformation, and desire to use stimulated during HCV treatment), and (5) Get Clean 
and Try It.  
The participants spoke about how their substance abuse evolved from inception to 
sobriety, and for some it remained a problem. Relapse and recovery were fragile in nature 
especially in these adults with HIV/HCV co-infection. The decision-making process is 
influenced by substance abuse experiences, however more research is needed to uncover 
specific factors influencing these decisions. 
xii 
Chapter I 
State of the Science 
Introduction 
Hepatitis C virus (HCV) infection affects between 150,000 to 300,000 human 
immunodeficiency (HIV) positive adults in the US (Alter et al., 1999; Sherman, Rouster, 
Chung, & Rajicic, 2002). The majority of co-infected adults (50%-90%) have acquired 
HCV through substance abuse (Centers for Disease Control [CDC], 1998; CDC, 2006b). 
Research has been conducted to understand substance abuse within the context of HIV 
infection (Buchanan et al., 2006; Doherty, Garfein, Monterroso, Brown, & Vlahov, 2000; 
Galai, Safaeian, Vlahov, Bolotin, & Celentano, 2003; Irwin et al, 1996; Mehta et al., 
2006; Nelson, Vlahov, Solomon, Cohn, & Munoz, 1995) and in HCV and HIV/HCV co-
infection (Fleming, Craven, Thornton, Tumilty, & Nunes, 2003; Nunes et al., 2006; 
Tracy Swan Treatment Action Group, 2006). Treatment decision-making can be difficult 
and complex for patients (Woolf et al., 2005) and these decisions can be influenced by a 
variety of factors such as health status, misinformation, emotions, and past experiences 
(Benbassat, Pilpel, & Tidhar, 1998; Redelmeier, Rozin, & Kahneman, 1993; Wills & 
Holmes-Rovner, 2006). Furthermore, not everyone wants the same level of involvement 
in the decision-making process (Levinson, Audiey, Kuby, & Thisted, 2004). In addition, 
much of the current research focuses on treatment decisions made by providers rather 
than the patient (Fultz et al., 2003; Patil et al., 2001; Sylvestre, 2005). Some research 
investigations have sought to understand treatment decisions made by HIV-infected and 
HCV-infected patients (Fraenkel, McGraw, Wongcharatraee, & Garcia-Tsao, 2005; 
Laws, Wilson, Bowser, & Kerr, 2000; Misener & Sowell, 1998). Current HCV treatment 
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guidelines suggest patients take a more active role in HCV treatment decision-making 
(National Institutes Of Health [NIH] Consensus Development Program, 2002). However, 
little is known about the substance abuse issues that may influence HCV treatment 
decisions among co-infected adults from their perspective (Fraenkel et al., 2005). Wagner 
and Ryan (2005) have suggested that research is needed to assess co-infected patients’ 
attitudes, beliefs, and readiness for HCV treatment along with factors influencing 
treatment decision-making. 
The purpose of this chapter is to describe substance abuse experiences among 
HIV/HCV co-infected adults and decision-making regarding HCV treatment. Also, this 
chapter will focus on studies, reviews, and treatment guidelines from the US due to the 
differences in cultural, legal, health care systems, and treatment options between 
countries. 
Prevalence of HIV and HCV and Co-infection 
HIV Prevalence 
An estimated 1 to 1.2 million persons are living with HIV/AIDS in the US (CDC, 
2006c; CDC, 2006d; Glynn & Rhodes, 2005). While sexual contact remains the leading 
risk associated with HIV infection, injection drug use is a significant source of new HIV 
infection in both men and women in the US (CDC, 2006a). For men, male-to-male sexual 
contact remains the primary mode of HIV transmission, followed by injection drug use 
and then heterosexual contact (CDC, 2006a; CDC, 2006b; CDC, 2006d). Black males are 
the largest group to be infected with HIV (CDC, 2006a; CDC, 2006c; CDC, 2006d). For 
women, heterosexual contact with HIV-infected males is the leading cause of infection, 
followed by sexual contact with male injection drug users, then sexual contact with 
2 
bisexual males. The overall number of women with newly diagnosed HIV infection has 
risen from 8% in 1985 to 27% in 2004 (CDC, 2006d). Black women outnumber white 
non-Hispanic women three-to-one in HIV/AIDS infections in the US (CDC, 2006a). 
There is no known cure for HIV however, advances in HIV care, treatment, and the 
introduction of combination antiretroviral therapy (ART) in 1996 have decreased 
mortality in HIV-infected adults as well as slowed HIV disease progression (Michaels, 
Clark, & Kissinger, 1998; Palella el al., 1998). 
HCV Prevalence 
Approximately 3.9 million individuals are living with HCV infection in the US 
and nearly twice as many men than women are infected (Alter et al., 1999; Alter, 2006; 
Butterfield et al., 2003; CDC, 2006b; Lauer & Walker, 2001).  In the National Health and 
Nutrition Survey (N = 10,612), the prevalence of HCV in males was 3.4% (2.6-4.4 at 
95% Confidence Interval [CI]) and 1.5% in females (1.1-2.0 at 95% CI) (Kruszon-Moran 
& McQuillan, 2005). It has been suggested up to five million Americans have been 
infected with HCV (Edlin, 2005). Historically, HCV was acquired through exposure to 
blood products or blood transfusions (CDC, 2006b; CDC, 1998). Currently, injection 
drug use is the primary source of newly diagnosed HCV infection in the US (CDC, 
2006a; CDC, 2006b; Edlin et al, 2005). Prevalence studies show HCV infection rates in 
injection drug users to be 67% (Piccolo et al, 2002), 76.9% (Garfein, Vlahov, Noya, 
Doherty, & Nelson, 1996), 89% (Thiede, Hagan, & Murrill, 2000), and 80% to 100% 
(Murrill et al., 2002). 
HCV is an enveloped ribonucleic acid (RNA) blood-borne virus of the 
Flaviviridae family and is categorized into six genotypes. Approximately 75% of adults 
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in the US are infected with genotype 1, 16% with genotype 2, and 8% with genotype 3 
(Nainan et al., 2006). Patients can also be infected with genotypes 4 to 6, but patients 
with these genotypes are less common in the US (Nainan et al., 2006). 
HCV is emerging as a major source of morbidity and mortality in the US. About 
30,000 new cases of HCV are diagnosed each year and approximately 85% of those will 
go on to develop chronic HCV infection (CDC, 2006d, Leung, 2002, CDC, 1998; Nainan 
et al., 2006; Sasadeusz, 2001). Approximately 8,000 to 10,000 people die each year from 
complications of liver disease and failure caused by HCV (CDC, 2006e; CDC, 1998). 
Currently, HCV infection accounts for one-third of hepatocellular carcinoma (HCC) 
cases in the US (NIH, 2002) and it has been estimated the number of persons with HCV 
induced liver failure will increase four-fold by the year 2018 (Lawrence, 2000). 
HIV/HCV Co-infection Prevalence 
HCV infection affects between 150,000 to 300,000 HIV positive adults in the US 
(Alter et al., 1999; Sherman et al., 2002). The overall prevalence rates of HIV/HCV co-
infection are difficult to determine (CDC, 2006e; Sherman, 2002). This is due to variation 
and delays in testing and reporting between state agencies and the cost of large 
population based studies (CDC, 2006e; Shepard, Finelli, & Alter, 2005). In addition, no 
national US database exists to track HIV/HCV co-infection rates. Reported co-infection 
rates range from 1.6% to 72.7 % (McCoy et al., 2004; Sherman et al., 2002; Tedaldi et 
al., 2003).  
In adults with HIV/HCV co-infection, mortality due to end-stage liver disease and 
liver failure is on the rise due to HCV infection (Bica et al., 2001). In a meta-analysis, 
Graham and colleagues (2001) concluded that co-infected patients had a six-fold greater 
4 
risk of liver decompensation (adjusted relative risk of 2.92 (95% CI, 1.70-5.01). HIV 
infection appears to increase HCV RNA levels (Sherman et al., 1993) and progression of 
HCV-related liver disease (Monga et al., 2001; Thomas et al., 2000). Merriman and 
colleagues (2006) found that HCV/HIV co-infection was associated with higher 
frequency of liver function abnormalities (37% vs 20%; p < 0.0003) and greater mortality 
(17% HCV/HIV vs 6% HCV vs 9% HIV p < 0.000) compared with mono-infected 
subjects.  
Also, HCV was found to increase the rate of HIV progression (Anderson, Guest, 
Rimland, 2004; De Luca et al., 2002; Piroth et al., 1998). In other studies, HCV was not 
associated with the progression of HIV or death due to AIDS (Staples, Rimland, & 
Dudas, 1999; Hershow et al., 2005; Sulkowski, Moore, Mehta, Chaisson, & Thomas, 
2002; Sullivan, Hanson, Teshal, Whotring, & Brooks, 2006). In a prospective trial (N = 
1955) no significant differences were found in the progression to AIDS, death, or 
responding to highly active antiretroviral therapy (HAART) between HCV-infected and 
HCV uninfected group (Sulkowski et al., 2002). The authors found an increased risk of 
death in a subgroup (n = 429) of HCV-infected patients with a baseline CD4 cell count of 
50/microL to 200/microL (relative hazard [RH], 1.51; 95% CI, 1.01-2.27). However, 
after adjusting for exposure to HAART in a multivariate Cox regression analysis, death 
was not independently associated with HCV infection in this subgroup (RH, 1.01; 95% 
CI, 0.65-1.56) (Sulkowski et al., 2002). 
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Substance Abuse Issues 
HIV and Injection Drug Abuse 
There has been considerable work done to understand substance abuse within the 
context of HIV infection (Doherty, Garfein, Monterroso, Brown, & Vlahov, 2000; Galai, 
Safaeian, Vlahov, Bolotin, & Celentano, 2003; Irwin et al, 1996; Mehta et al., 2006; 
Nelson et al., 1995). Injection drug use (IDU) is the second leading risk factor associated 
with new HIV infections in the US (CDC, 2006a). Studies show a multitude of risk 
factors exist in the transmission of HIV in injection drug users. 
Reported risk factors for HIV in injection drug users include: 
• Injecting heroin to mediate the effects of crack cocaine smoking (Irwin, 
1996), 
• Moving from snorting heroin to injecting heroin to improve the high 
(Doherty  et al., 2000; Irwin et al., 1996), 
• Injecting heroin or cocaine out of curiosity or for fun (Doherty et al., 
2000), 
• Poly-substance abuse (using a variety of drugs and alcohol to get a high) 
(Doherty et al., 2000; Irwin et al., 1996), 
• Injecting a speedball (the mixing of heroin and cocaine  in the same 
syringe) (Doherty et al., 2000), 
• Having a sexual partner who injects or trades sex for drugs and money 
(Galai et al., 2003; Irwin et al., 1996), 
• Sharing needles with one or more persons in a shooting gallery (Doherty, 
et al., 2000; Galai et al., 2003; Mehta et al., 2006), with a sexual partner 
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who provides emotional support (Unger et al., 2006), and with an injection 
partner if HIV status has been discussed (Unger et al., 2006), 
• Indirect sharing of drug preparation equipment (cotton, straws, rinse 
water, cookers) (Koester, Glanz, & Baron, 2005; Thorpe et al., 2002; 
Tortu, McMahon, Hamid, & Neaigus, 2003). 
Injection drug abuse continues to be a major source of HIV infection in the US. 
Greater numbers of adults are living with HIV infection than ever before due to the 
improvements in treatment (CDC, 2006c). HIV prevention efforts should be directed 
toward individuals who have a history of injection drug use and other high risk behaviors 
(Edlin et al., 1994; Nelson et al., 2002). Drug detoxification and rehabilitation remains a 
priority for injection drug users (Institute of Medicine [IOM], 2007). Several studies have 
shown that those in methadone treatment programs have lower rates of HIV 
seroconversion (Metzger et al., 1993; Moss et al., 1994). In a review of the literature, 
Gibson, Flynn, and McCarthy (1999) concluded that methadone treatment programs are 
effective in preventing HIV disease among injection drug users. 
HIV and Alcohol Abuse 
Injection drug users frequently abuse alcohol which can influence high risk 
decision-making behaviors (Stein et al., 2000; Stein et al., 2002). Alcohol ingestion is 
known to reduce inhibition and judgment skills (Abroms, Fillmore, & Marczinski, 2003; 
Marczinski & Fillmore, 2005). The use of alcohol has been reported as an independent 
risk factor for needle sharing among injection drug users (Stein et al., 2000). In addition, 
it has been shown that when drinking, injection drug users are more likely to visit 
shooting galleries compared to days when they did not drink (p < .001) (Stein et al., 
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2002). Thus, alcohol abuse can increase the risk of HIV in injection drug users (Doherty 
et al., 2000; Galai et al., 2003; Mehta et al., 2006). 
HCV and Injection Drug Abuse 
There are a number of studies that address HCV infection and substance abuse 
issues (Garfein et al., 1996; Hagan et al., 2005; Klinkenberg et al., 2003; Osher et al., 
2003; Thorpe et al., 2002; Tortu, McMahon, Pouget, & Hamid, 2004). Transmission of 
HCV can occur rapidly after initiating IDU. Garfein and collegues found that 65% of 
injection drug users in their sample were infected with HCV within the first year of IDU 
(Garfein et al., 1996). Hagan, Thiede, and Des Jarlais (2005) found that 134 of 484 (28%) 
of HCV antibody negative injection drug users seroconverted to HCV positive within a 
weighted average time of 3.4 years. Additionally, the risk of HCV infection increases 
with the duration of IDU; close to 100% of injection drug users are infected by year eight 
of IDU (Kwiatkowski, Fortuin-Corsi, & Booth, 2002; Murrill et al., 2002). Reported risk 
factors for HCV infection in the injection drug user include: 
• Sharing used needles (Hagan et al., 2005), 
• Sharing injection drug preparation paraphernalia (cotton, cooker, rinse 
water) (Hagan, Thiede, Weiss, Duchin, & Alexander, 2001; Kwiatkowski 
et al., 2002). 
• Sharing non-injection drug paraphernalia (intranasal and oral drug 
implements) (Tortu et al., 2004).  
IDU practices place individuals at risk for HCV infection (Hagan et al., 2005; 
Sherman et al., 2002). Targeted prevention programs such as needle exchange programs, 
sterile syringe prescriptions, and risk-reduction programs designed specifically for the 
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prevention of HIV and HCV transmission are needed (Hagan et al., 2005; NIH, 2002). 
Encouraging patients to participate in prevention programs along with drug detoxification 
and rehabilitation, especially early in injection drug use initiation, may help reduce the 
transmission of HCV infection (Hagan et al., 2005). 
HCV and Alcohol Abuse 
Alcohol abuse can co-occur with HCV infection and can worsen the course of the 
HCV disease (Campbell et al., 2006; Nunes et al., 2006; Peters & Terrault, 2002). Studies 
have shown a high prevalence of HCV infection in patients who abuse alcohol (Anand et 
al., 2006; Campbell et al., 2006). In the longitudinal Study to Reduce Intravenous 
Exposures (STRIVE), 37% of the sample (n = 598) were problem drinkers based on the 
10-item Alcohol Use Disorder Identification Test (AUDIT) (Campbell et al., 2006). In 
the final multivariate model within this study, problem drinking was associated with male 
gender (adjusted odds ratio [AOR] = 2.5, 95% CI = 1.5-4.3), homelessness (AOR = 1.6, 
95% CI = 1.1-2.5), prior alcohol treatment (AOR = 3.7, 95% CI = 2.4-5.7), injection drug 
use within the past three months (AOR = 2.0, 95% CI = 1.3-3.1), and depression (AOR = 
1.7, 95% CI = 1.1-2.6) (Campbell et al., 2006). 
Alcohol use can increase the risk of developing liver fibrosis in persons infected 
with HCV (Peters & Terrault, 2002; Schiavini et al., 2006; Thomas et al., 2000). In an 
integrative review, these authors concluded that heavy alcohol ingestion (more than 50 
grams/day) may worsen liver fibrosis in adults with HCV infection (Peters & Terrault, 
2002). Other studies have shown that patients with HCV infection and concurrent alcohol 
use have a more rapid progression of liver disease (Di Martino et al., 2001; Poynard, 
Bedossa, & Opolon, 1997). Westin and colleagues (2002) found that moderate alcohol 
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intake (4.8 grams/day, interquartile range 1.1-11.6 grams/day) increased fibrosis 
progression in adults with HCV infection. The authors suggested that patients with HCV 
infection should abstain from alcohol consumption (Westin et al., 2002). The National 
Institutes of Health Consensus guidelines suggest alcohol ingestion is not an absolute 
contraindication to HCV treatment, however safe levels of consumption have not been 
established and patients should be encouraged to abstain before and during treatment 
(NIH, 2002). 
HIV/HCV Co-infected Adults and Injection Drug Abuse  
According to recent statistics, the majority of new HIV/HCV co-infected adults 
(60% to 90%) acquired HCV through injection drug abuse (CDC, 1998; Thomas et al., 
1995; Thomas, 2002; Shepard et al., 2005). Many of the same risk factors associated with 
HIV or HCV mono-infection places the injection drug user at risk for HIV/HCV co-
infection. Reported risk factors for HIV/HCV co-infection in injection drug users include: 
• Direct contact of blood through sharing needles and syringes (Hsu, 2002; 
Novelli et al., 2005),  
• Sharing drug preparation equipment such as cotton, cookers, straws, and 
rinse water (Koester, Glanz & Baron, 2005; Thorpe et al., 2002; Tortu, 
McMahon, Hamid, & Neaigus, 2003),  
• Sharing used needles and syringes with sexual partners, having 
unprotected sex or trading sex for money or drugs, or having sex with 
someone who injects drugs (Miller, & Neaigus, 2001). 
HIV-infected patients and anyone with a history of IDU should be screened for 
HCV infection in order to identify those who may need HCV treatment (Alter, 2005; 
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CDC, 1998; NIH, 2002; Sherman, 2002a; Sherman, 2002b; Strader, Wright, Thomas, & 
Seeff, 2004). With treatment, HCV-related liver failure may be reduced in HIV/HCV-
infected patient (Sherman, 2005b). 
HIV/HCV Co-infection and Alcohol Abuse  
Alcohol abuse is common in HIV/HCV co-infected patients (Nunes et al., 2006). 
Alcohol consumption has been shown to increase HCV RNA, aspartate aminotransferase 
(AST), and gamma-glutamyl transpeptidase (GGT), and alanine transaminase (ALT), and 
progression of liver disease in patients with HIV/HCV co-infection (Cooper & Cameron, 
2005; Conigliaro et al., 2003; Nunes et al., 2006; Pol et al., 1998). In addition, alcohol 
consumption can increase hepatotoxicity in those patients who are taking HIV 
antiretroviral medications (Hernandez et al., 2001; Soriano et al., 2002).  
Persistence of Substance Abuse 
Despite the number of inpatient and outpatient drug and alcohol treatment 
programs in the US, relapse and persistent substance abuse remains a major problem for 
those who abuse drugs and alcohol (IOM, 2006). Persistent IDU places the individual at a 
greater risk for contracting HIV/HCV infections (Galai, Safaeian, Vlahov, Bolotin & 
Celentano, 2003; Lucus et al., 2006; Mehta et al., 2006). Substance abuse tends to emerge 
gradually and persists on a continuum (Miller & Carroll, 2006). For example, an 
individual who smokes cocaine may need to move to injecting heroin to mitigate the 
withdrawal effects of cocaine (Irwin, 1996). Or, drug escalation may occur to improve 
the high (Doherty, Garfein, Monterroso, Latkin, & Vlahov, 2000). Addictive behaviors 
tend to be self-perpetuating and reinforced as part of other psychological, social, and 
physical problems such as mood/psychiatric disorders, homelessness, violence, poverty, 
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and neglect (Mehta et al., 2005; Miller & Carroll, 2006). As tolerance increases, 
dependence sets in, causing repetitive drug use (Hyman & Malenka, 2001). This pattern 
of tolerance and dependency can be persistent and reinforced due to compulsive 
psychological mechanisms, as well as neurochemical changes in the cells (Hyman & 
Malenka, 2001; Hyman, Malenka, & Nestler, 2006). In addition, there is some evidence 
that structural deficiencies within the grey matter of the brain exist associated with 
decision-making behavioral inhibition and emotions in persons who abuse cocaine 
(Childress, 2006; Franklin et al., 2002). Thus, with exposures to cues and reinforcement, 
persistent drug abuse can be a life-long behavior (Childress, 2006; Volkow et al., 2006; 
White, 1989). 
Patients with persistent IDU are at risk for HIV and HCV infections and have a 
higher mortality rate than in those with HIV/HCV co-infection who do not inject drugs 
(Galai et al., 2003). The AIDS Link to Intravenous Experience (ALIVE) study revealed 
only 19.6% of the total participants (N = 1,339) were able to abstain from substance 
abuse during the 12-year study period (Galai et al., 2003). In addition, persistent injection 
drug users (29.2%) and those who had multiple relapses (36.9%) had the highest rates of 
mortality due to AIDS, with deaths at 21% and 20.2% respectively. Greater efforts need 
to be placed on detoxification and treatment of active substance abuse before beginning 
HCV treatment (Soriano et al., 2002). 
Treatment of HCV in HIV/HCV Co-infected Adults 
Treatment of HCV in Adults 
The primary purpose of treatment of HCV in an HCV mono-infected or 
HIV/HCV co-infected adult is to either eradicate HCV or reduce the likelihood of HCV-
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related liver disease including cirrhosis and liver cancer. The main goal of HCV 
treatment is to achieve a sustained viral response (SVR). An SVR is defined as the 
absence of a detectable HCV-RNA six months after the completion of treatment 
(Ballesteros et al., 2004; Hughes & Shafran, 2006; Manns et al., 2001; Strader et al., 
2004). HCV-RNA is the direct serological measure of the HCV virus. Several drug 
combinations have been approved by the Federal Drug Administration (FDA) for the 
treatment of HCV in the mono-infected adult (Stader, Wright, Thomas, & Seeff, 2004). 
The approved combination therapies include: 
• Peginterferon alfa-2a (Pegasys, Hoffmann-La Roche, NJ) and ribavirin, 
• Peginterferon alfa-2b (Peg-Intron, Shering-Plough, NJ) and ribavirin, 
• Interferon alfa-2a (Roferon-A, Hoffmann-La Roche, NJ) and ribavirin, 
and 
• Interferon alfa-2b (Inron-A, Shering-Plough, NJ) and ribavirin. 
However, alfa interferons and the recombinant forms (alfa-2a, alfa-2b, and 
consensus interferon) are being replaced with pegylated interferons (peginterferons) 
(NIH, 2002). This is because pegylated interferons have a longer half-life than alfa 
interferons and can be given once a week rather than multiple times a week (National 
Digestive Disease Information Clearinghouse [NDDIC], 2006). The once-a-week dosing 
of peginterferons make it easier for patients to adhere to treatment since they are only 
receiving one injection per week versus three. Pegylated alfa-2a is a standard dose (180 
micrograms/subcutaneous injection/once weekly in combination with ribavirin) and 
pegylated alfa-2b is based on an individual’s weight (1.5 microgram/kilogram body 
weight/subcutaneous injection/once weekly in combination with ribavirin). Treatment is 
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recommended for a duration of 24 or 48 weeks in HCV mono-infected adults depending 
on HCV genotype (Strader et al., 2004). A full 48-week course of HCV treatment 
peginterferon plus ribavirin costs approximately $20,000 (Raymond, 2004; Solomon, 
Weinstein, Hammitt, & Goldie, 2003). 
Treatment of HCV in HIV/HCV Co-infected Adults 
Interferon alfa-2a and interferon alfa-2b are FDA approved for use in HIV/HCV 
co-infected adults (Thomas, 2006). Pegylated interferon alfa-2a or interferon alfa-2b plus 
ribavirin are the current treatment choices for chronic HCV in HIV co-infected adults and 
are prescribed for 48 weeks (Carrat et al., 2004; Voigt et al., 2006). Guidelines suggest 
that an HCV-RNA test should be performed at week 12 of therapy to assess for early 
viral response (EVR) (Strader et al., 2004). EVR is defined as an undetectable HCV-
RNA or a reduction in the HCV-RNA level by 2 log or more which happens at 
approximately 12 weeks of therapy and can be indicative of SVR (Torriani et al., 2004). 
In three randomized clinical trials, EVR predicated 97.5% to 100% of non-responders of 
HCV treatment (Chung et al., 2004; Fuster et al., 2006; Torriani et al., 2004). If an EVR 
is not achieved, treatment can be discontinued in an effort to mitigate the medication side 
effects and the cost of treatment. Fuster and colleagues (2006) found that there was no 
benefit to extending interferon alfa-2a plus ribavirin past 12 weeks in HIV/HCV co-
infected patients if EVR was not achieved at 12 weeks. 
There are modifiable physiological and psychological contraindications to HCV 
treatment in the HIV/HCV co-infected adult. Before HCV treatment begins, the patient 
should undergo stabilization of HIV infection with HAART, stabilization of active 
psychiatric disease, and management of active substance abuse (Edlin et al., 2005). 
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Management of active substance abuse can include the use of buprenorphine or opioid 
agonists such as methadone alone or in combination with psychotherapy. Treatment of 
alcohol abuse is also part of the initial pretreatment phase. Patients should be encouraged 
to enroll in an alcohol treatment program before beginning HCV treatment; however this  
should not prevent the individual from being assessed for treatment (NIH, 2002). 
Treatment of HCV infection is not recommended in HIV/HCV co-infected adults 
who have advanced cirrhosis, comorbidities with a limited life expectancy, renal failure, 
malignancies, uncontrolled autoimmune disorders, pregnancy or potential pregnancy 
(among those refusing to use birth control measures), and in those with heart, lung, or 
kidney transplantations (CDC, 2006e; Yee, Currie, Darling, & Wright, 2006; CDC, 
1998). In patients who have contraindications for HCV treatment, management of drug 
and alcohol use, may slow progression of liver fibrosis (Adeyemi, 2007). 
Since the progression to cirrhosis is faster and the mortality related to liver failure 
in HIV/HCV co-infected adults is increasing, efforts to move patients toward HCV 
treatment is warranted (Eldin et al., 2005; DiMartino et al., 2001). Brau (2005) suggests 
all patients with HIV/HCV co-infection should be evaluated for treatment. 
Treatment Response Rates in HIV/HCV Co-infected Adults 
The rates of SVR in HCV mono-infected adults ranges from approximately 40% 
to 80% depending on HCV genotype (Fried et al., 2002; Manns et al., 2001). In adults 
with HIV/HCV co-infection, SVR is generally lower than in HCV mono-infected adults 
(Sherman, 2003; Shire, Welge, & Sherman, 2007). Two randomized controlled trials 
have examined HCV treatment in HIV/HCV co-infected adults with standard interferon 
alfa-2b (INF-2b) and ribavirin (Brau et al., 2004; Sulkowski et al., 2004). The SVR was 
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11% and 9%, respectively. Peginterferon alfa-2a plus ribavirin and pegylated interferon 
alfa-2b plus ribavirin have been shown to be more effective than standard interferon alfa-
2a or standard interferon alfa-2b and ribavirin (Chung et al., 2004; Carrat et al., 2004) in 
randomized clinical trials. In the AIDS Pegasys Ribavirin International Co-infection Trial 
(APRICOT), peginterferon alfa-2a plus ribavirin was shown to be more effective than 
either peginterferon alfa-2a as monotherapy, or standard interferon alfa-2a plus ribavirin 
(Torriani et al., 2004). 
SVR rates vary in adults with HIV/HCV co-infection. Reported SVR rates in 
randomized trials examining peginterferon alfa-2b plus ribavirin versus standard 
interferon alfa-2b plus ribavirin include: 
• In the International Hepatitis Interventional Therapy Group: 54% (n = 
274/511) in peginterferon alfa-2b plus ribavirin compared to two different 
arms: 1) 47% in standard interferon alfa-2b plus ribavirin (n = 235/505) or 
2) 47 % in lower dose peginterferon alfa-2b (n = 244/514) (p = .01 for 
both comparisons) (Manns et al., 2001). 
• 44% in peginterferon alfa-2b plus ribavirin arm (n = 52) compared to 7% 
in standard interferon alfa-2b plus ribavirin arm (n = 43) (p = .007) 
(Laguno et al., 2004). 
• 27% in peginterferon alfa-2b arm (n = 205) compared to 20% in standard 
interferon alfa-2a plus ribavirin arm (n = 207) (p = .047) (Carrat et al., 
2004). 
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Reported SVR rates in peginterferon alfa-2a plus ribavirin versus standard 
interferon alfa-2a plus ribavirin include: 
• The APRICOT Trial: 40% in peginterferon alfa-2a plus ribavirin arm (n = 
224) compared to 12% in standard interferon alfa-2a plus ribavirin arm (n 
= 178) (p = .001) (Torriani et al., 2004), 
• The Adult AIDS Clinical Trial Group (ACTG): 27% in peginterferon alfa-
2a plus ribavirin (n = 6) compared to 12% (n = 67) in standard interferon 
alfa-2a plus ribavirin arm (p = .03) (Chung et al., 2004). 
In each study, the peginterferon alfa arm was the most effective (Carrat et al., 2004; 
Chung et al., 2004; Laguno et al., 2004; Manns et al., 2001; Torriani et al., 2004). 
Currently, ribavirin plus either peginterferon alfa-2a or peginterferon alfa-2b is the 
standard of care for treatment of HCV in HIV/HCV co-infected adults in the US 
(Thomas, 2006). 
Research has demonstrated a wide variation in HCV treatment response rates in 
the various genotypes. Patients with genotype 1 have the lowest treatment response rate 
(Simmonds, 1999; Nainan et al., 2006; Shire, Welge, & Sherman, 2007). Treatment 
response rates in patents with genotype 1 treated with peginterferon alfa-2a plus ribavirin 
range from 14% to 29% (Chung et al., 2004; Torriani et al., 2004). In those treated with 
peginterferon alfa-2b plus ribavirin, SVR rates range from 10% to 38% (Cargnel et al., 
2005; Carrat et al., 2004; Laguno et al., 2004). Some early research results indicate that a 
higher dose of ribavirin at 1000 mg to 1200 mg versus 800 mg, may play a more critical 
role in achieving SVR, especially in patients with HCV genotype 1 and in those with 
HIV/HCV co-infection (Ramos et al., 2007). 
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Only a few observational studies have included active substance abusers in HCV 
evaluation studies (Backmund, Meyer, von Zeilonka, & Eichenlaub, 2001; Schaefer et 
al., 2003; Sylvestre, 2002; Sylvestre, Litwin, Clements, & Gourevitch, 2005). Sylvestre 
and colleagues (2005) examined a group of individuals infected with HCV (N = 76) in a 
methadone maintenance program and treated with interferon alfa-2b and ribavirin. The 
authors found those who used substances (heroin, cocaine, methamphetamines) regularly 
during HCV treatment (n = 8) did not achieve SVR. These findings did not reach 
statistical significance (p = .09). However, a progressive decrease in SVR was seen 
among those treated as substance abuse increased.  
HCV Treatment Rates in HIV/HCV Co-infected Adults 
The numbers of HIV/HCV co-infected patients treated for HCV infection are low 
(approximately 15%) (Taylor, Costello, Alt, Yates, & Tashima, 2002). Furthermore, co-
infected substance abusers have lower HCV treatment rates than non-substance abusers 
(Fultz et al., 2003; Taylor et al., 2002). Reported HCV treatment rates in co-infected 
adults range from 0.2% (N = 881) in a group of military veterans (Fultz et al., 2003) to 
15% (N = 104) in an urban setting in New York (Restrepo et al., 2005). 
There have been numerous studies examining medical treatment of HCV in the 
adult with HIV/HCV co-infection (Chung et al., 2004; Fleming et al., 2003; Laguno et 
al., 2004; Nunes et al., 2006; Taylor, 2005; Torrriani et al., 2004). The findings suggest 
there are many barriers to HCV treatment. 
Barriers to HCV Treatment in HIV/HCV Co-infected Adults 
Treatment rates for HCV infection in adults co-infected with HIV/HCV remain 
low (Clanon, Mueller, & Harank, 2005; Mehta et al., 2005). HCV treatment can be 
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challenging and complex in the co-infected substance abuser. Therefore, HCV treatment 
decisions should be based on a collaborative process between provider and the patient 
(Fleming, Tumilty, Murray, & Nunes, 2005; Mehta et al., 2005). Due to low HCV 
infection treatment rates in adults with HIV/HCV co-infection, a greater understanding of 
the factors contributing to treatment decisions from the patient and provider perspective 
are needed (Wagner & Ryan, 2005). Low HCV treatment rates in HIV/HCV co-infected 
adults can be due to a variety of structural, personal, and social barriers. 
Structural Barriers to HCV Treatment  
Structural barriers are obstacles that are generally not controlled by the patient. 
Structural barriers to HCV treatment include issues such as treatment guidelines, provider 
decision-making about treatment eligibility or ineligibility, limited access to care, limited 
appointments with HCV treatment specialists, and difficulty accessing HCV treatment 
programs (Edlin, 2002; Edlin et al., 2001; Edlin et al., 2005; Mehta et al., 2005; 
Thompson, Ragland, Hall, Morgan, & Bangsberg, 2005). 
Individual health care systems have guidelines to assist providers in delivering 
care to adults requiring treatment of HCV infection (National Institutes of Health [NIH], 
1997, NIH, 2002; Thompson et al., 2005; Yee et al., 2006). Historically, treatment 
guidelines excluded persons from HCV treatment who were drinking alcohol and 
injecting illegal drugs until a six-month period of sobriety had been established (CDC, 
1998; NIH, 1997). Changes in HCV treatment guidelines now allow providers to assess 
the risks and benefits of treatment in active substance abusers (NIH, 2002). Active 
alcohol and active substance abuse are considered relative contraindications to HCV 
treatment and the patient should be encouraged to enroll in a drug or alcohol treatment 
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program before beginning HCV treatment (Adeyemi, 2007; NIH, 2002; Nunes et al., 
2006; Soriano et al., 2002; Sulkowski & Thomas, 2005a). Despite these changes to 
treatment guidelines, active alcohol and injection drug abuse remains a significant barrier 
for the treatment of HCV in HIV/HCV co-infected adults (Fleming et. al. 2003; Fultz et 
al., 2003; Nunes et al., 2006; Thompson et al., 2005; Walley, White, Kushel, Song, & 
Tulsky, 2005; Sylvestre, 2005). Nunes and colleagues (2006) found that active alcohol 
abuse was the largest barrier to HCV treatment in HIV/HCV co-infected adults. These 
researchers found that 54 of 200 patients (27%) were ineligible for HCV treatment due to 
current heavy alcohol abuse (defined as more than 14 standard drinks per week or more 
than four drinks per day for men, more than seven drinks per week or more than three 
drinks per day in women). In this same study, 17 of the 200 (8.5%) patients were 
ineligible for HCV treatment due to active IDU (Nunes et al., 206). In a prospective study 
from The US Department of Veterans Affairs (VA) to assess HCV treatment candidacy 
and adherence and outcomes, 80% of the sample (584/726) had a history of alcohol use 
and 27% (194/726) had used alcohol regularly in the past year (Anand et al., 2006). 
These authors found that alcohol consumption was associated with increased HCV 
treatment discontinuation (40% vs. 26%; p = < .0002), but not SVR (p =.06). 
Sylvestre and colleagues (2005) suggest that arbitrary abstinence times should not 
be used as a criterion for beginning HCV treatment; rather, individual assessment should 
take place in order to determine HCV treatment options. Furthermore, it has been 
suggested that withholding HCV treatment in active substance abusers is unwarranted 
and unethical (Geppert & Arora, 2005). Withholding treatment can delay access to 
necessary health care and can pose a threat to public health by allowing the virus to go 
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untreated (Edlin et al., 2001; Geppert & Arora, 2005). Edlin (2002) suggests allowing 
patients to attempt HCV treatment if they want to try. Conversely, others have suggested 
medical efforts be placed on detoxification and treatment of active substance abuse 
before HCV treatment is initiated (Soriano et al., 2002).  
Additionally, healthcare providers make decisions about HCV treatment 
eligibility or ineligibility (Thompson et al., 2005). There may be a lack of referral for 
treatment due to provider decision-making.  In a study investigating eligibility, providers 
(N = 52) classified 70% (94/133) of HIV/HCV co-infected individuals as ineligible for 
HCV infection treatment (Thompson et al., 2005). In addition, the providers in this 
sample concluded that patients would be ineligible for HCV treatment because of poor 
medication adherence, lack of interest in treatment, active depression, and active IDU. 
The authors went on to assess HCV treatment rates in the patients. They found that out of 
the total sample (N = 133) 13.8% (4/133) started HCV treatment, two of the four patients 
completed HCV treatment and one achieved SVR. A major consideration in this patient 
population was that most were homeless or marginally housed. In another study, the 
authors found that injection drug users would be motivated to undergo HCV evaluation 
and treatment. However in this study, treatment rates were not assessed (Stein, Maksad, 
& Clarke, 2001). 
Limited access to HCV treatment specialists and treatment programs exist from a 
structural perspective (Edlin et al., 2005; Litwin, Soloway, & Gourevitch, 2005). There 
may be a limited number of appointments and therefore, long wait times to be evaluated 
by a gastroenterology (GI) specialist due to a finite number of specialists in a given 
geographical location (Edlin et al., 2005; Clanon et al., 2005; Fishbein, Lo, Reinus, 
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Gourevitch, & Klein, 2004; Thompson et al., 2005). The wait to see a GI specialist can be 
up to six months (Thompson et al., 2005). 
To help alleviate access to HCV treatment, alternative programs are being 
developed to provide comprehensive care to those with HCV infection or HIV/HCV co-
infection. For example, the VA has the National Hepatitis C Program and the National 
HIV/AIDS Program and has specific treatment guidelines for HCV and HIV/HCV co-
infected veterans (Tien & Wright, 2005; Yee et al., 2006). The VA system estimates 
approximately 5% to 10% of veterans who receive care through the VA system are 
infected with HCV and 40% of those are co-infected with HIV (Tien & Wright, 2005; 
United States Veterans Affairs, 2005; Yee et al., 2006). Despite having one of the largest 
treatment programs in the US for HCV and HCV/HIV co-infected patients (Backus, 
Boothroyd, & Deyton, 2005; Philips, Mole, Backus, Halloran, & Chang, 2003), there are 
reported barriers to HCV evaluation and treatment and low HCV treatment rates in the 
VA medical system (Fultz et al., 2003). In a study to evaluate characteristics of 
HIV/HCV co-infected patients who received a pretreatment workup, the authors found 
that adults with HIV/HCV co-infection had higher rates of HCV pretreatment laboratory 
tests compared to those with HCV mono-infection (Backus, Boothroyd, Phillips, & Mole, 
2006). These researchers suggest that these findings may be due to frequent clinic visits 
for HIV disease management rather than for a specific HCV workup. Approximately 
11% (377/4135) of the sample started HCV treatment. Positive predictors of treatment 
initiation included a higher CD4 count (p = .001), non-Hispanic white race (p = .001), 
receiving ART (p = .001), and having an undetectable HIV viral load (p = .001). 
Negative predictors of HCV treatment in this sample included chronic mental illness (p < 
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.05) and a history of hard drug abuse (p = .001) (Backus et al., 2006). In this study, hard 
drug abuse was defined as the documented use of opiates, cocaine, or amphetamines 
within the past year. 
Other programs have been developed to deliver HCV treatment outside traditional 
gastroenterology clinics. For example, HCV treatment is being delivered in methadone 
maintenance programs (Litwin, Soloway, & Gourevitch, 2005; Sylvestre et al., 2005), a 
community HIV clinic (Clanon et al., 2005), and a comprehensive HIV clinic associated 
with large medical center (Adeyemi et al., 2004). These clinics have provided access to 
HCV evaluation for approximately 300 adults with HCV mono-infection or HIV/HCV 
co-infection. Substance abuse treatment programs, primary care providers, infectious 
disease clinics, and addiction specialty clinics may also be able to provide the 
infrastructure for points of entry for HCV evaluation and treatment (Edlin et al., 2005; 
Kresina, Bruce, Cargill, & Cheever, 2005; Mehta et al., 2005; Walley et al., 2005). These 
alternative programs may help expand the access to HCV evaluation and treatment in 
populations that may have difficulty accessing GI specialists.  
Personal Barriers to HCV Treatment 
Personal barriers can impede evaluation and treatment of HCV in adults with 
HIV/HCV co-infection (Edlin et al., 2005). These barriers can include limited knowledge 
of HCV treatment, fear of treatment and treatment side effects, or lack of follow-up with 
appointments or referrals (Clanon et al., 2005; Fishbein et al., 2004; Restrepo et al., 2005; 
Taylor, 2005; Walley, White, Kushel, Song, & Tulsky, 2005). However, many personal 
barriers such as fear and lack of knowledge can be modified with education and support 
by the healthcare team (Fleming et al., 2003; Taylor, 2005).  
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Limited knowledge or information about HCV treatment options can prevent a 
patient’s ability to make an informed decision about treatment (Walley et al., 2005). The 
lack of knowledge about HCV infection can start with not knowing his/her HCV 
infection status. Providers should offer HCV testing to all patients with HIV infection and 
to anyone with a history of percutaneous blood exposure (Edlin, 2005; Kontorinis, 
Agarwal, & Dieterich, 2005). Providers should work to educate patients about HCV 
infection, transmission risks, treatment options, and risks and benefits of HCV treatment 
(Struss, Astone, Hagan, & Des Jarlais, 2004). 
Also, patients can be reluctant to start HCV treatment due to fear (Fleming et al., 
2003; Fleming et al., 2005). Fear can be associated with medication side effects, liver 
biopsy, and the act of self-injecting interferon which might trigger relapse of injection 
drug use (Fishbein et al., 2004).  
Other reported personal barriers to HCV evaluation and treatment include lack of 
follow-up on referrals, appointments, and evaluation workups (Fishbein et al., 2004; 
Oluwatoyin et al., 2004; Thompson et al., 2005). Even when patients are referred for 
HCV treatment, few patients with substance abuse disorders take advantage of the 
referral and even fewer receive treatment (Fishbein et al., 2004). Fishbein and colleagues 
(2004) found that active alcohol and drug abusers were less likely to accept referral for 
HCV evaluation (odds ratio adjusted [OR adj], 0.51, 95% CI 0.30-0.88). However, 
having HIV/HCV co-infection was associated with accepting a referral for HCV 
evaluation for treatment (OR adj, 0.51, 95% CI, 0.30-0.88). In the patients with 
HIV/HCV co-infection, having a history of IDU was associated with accepting a referral 
for HCV evaluation (OR adj, 3.60, 95% CI, 1.08-11.96). Despite patients’ willingness to 
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accept the referral, only one-third (n = 21) kept their appointment; of this group, five 
underwent a liver biopsy, and only one person started HCV treatment (Fishbein et al., 
2004). Notably, patients with HIV infection were more likely (p < .001) to keep their 
appointment for the HCV evaluation process than those with HCV mono-infection 
(Oluwatoyin et al., 2004). 
Social Barriers to HCV Treatment 
Social barriers related to HCV treatment ranges from individual to community 
level issues (Edlin et al., 2005) and can include homelessness, joblessness, lack of 
transportation, lack of family support, and other family issues (Clanon et al., 2005; 
Fleming et al., 2005; Mehta et al., 2005). Difficulty in accessing HCV treatment 
programs is a problem for marginalized or disadvantaged populations (Strader, 2002; 
Thompson et al., 2005). Research is beginning to address social issues related to 
treatment access in HIV/HCV co-infected adults in the inner-city, the urban poor, and 
recovering injection drug users (Fleming et al., 2003; Fleming et al., 2005; Sylvestre et 
al., 2005). Many patients rely on public health systems for evaluation and treatment of 
HCV infection and delays in evaluation can be lengthy for these individuals (Thompson 
et al., 2005). Hall and colleagues (2004) examined a sample of HIV positive homeless 
and marginally housed urban adults and found that non-white individuals (OR, 0.26, 95% 
CI. –0.11 to 0.62, p < .01) and injection drug users were less likely to receive HCV 
testing (OR, 0.14, 95% CI, -0.19- to 0.92,  p < .05). These authors also found that only 
38/249 (21%) of the HCV positive individuals in the study reported receiving a referral to 
a GI specialist for HCV treatment and only 7/249 (3.8%) reported receiving HCV 
treatment. The individual barriers were not assessed in this study. However, the study 
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illustrates the need for research to assess the barriers to HCV treatment in disadvantaged 
populations.  
Patient Treatment Decision-Making Process 
Historically, research on medical decision-making has focused on understanding 
how healthcare providers make treatment decisions and the development of tools to assist 
in the decision-making process (e.g., decision aides, treatment guidelines, and computer 
assisted-technologies) (Kaplan, Ganiats, & Frosch, 2004; Patel, Kaufman, & Arocha, 
2002). Decision-making research evaluates decision-making characteristics based on 
hypothetical treatment scenarios (Patel et al., 2002). However, there is a shift towards 
understanding patient treatment decision-making through naturalistic inquiry and in 
diverse settings (Patel et al., 2002; Wills & Homes-Rovner, 2006).  
Decisions regarding healthcare have moved from a paternalistic model to a 
collaborative or shared approach between the healthcare provide and the patient (Deegan 
& Drake, 2006; Thomasma, 1983; Quill & Brody, 1996). The National Institute of 
Mental Health (NIMH, 1999) and the Committee on Quality Health Care in America 
Institute of Medicine (IOM) (2001) suggest healthcare providers enlist the patient’s 
active participation in decisions about care. The inclusion of patient autonomy and values 
should be an integral part of the treatment decision-making process (Committee on 
Quality Health Care in America Institute of Medicine, 2001). Healthcare providers are 
faced with providing the necessary support and education to the patient in order for them 
to be more involved with treatment decision-making (Woolf et al., 2005). However, 
research is needed to understand the patient’s perspective and understanding of the 
decision-making processes (Deegan & Drake, 2006; Straus, 2002). 
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Patients are routinely asked to participate in decisions about their health care 
(Pierce & Hicks, 2001). Current research reveals that patients prefer shared decision-
making with their healthcare providers. Patients also want to be informed about their 
treatment choices, possible side effects, and preferences for health care (Bruera, Willey, 
Palmer, & Rosales, 2001; Levinson, Kao, Kuby, & Thisted, 2005; Murray, Pollack, 
White & Lo, 2006; Stiggelbout & Kiebert, 1997). In an integrative review of patient 
preferences and decision-making, Benbassat and colleagues (1998) concluded patients 
wanted to be informed about their illness (92% of the time) but there was variability 
among individuals in preferences about their participation in decision-making. Levinson 
and colleagues (2004) conducted a population-based study (N = 2,765) and concluded 
that 96% of the participants wanted to be offered treatment options.  
Patient decision-making is considered a process (Hicks & Holm, 2003; Pierce & 
Hicks, 2001; Theroux & Taylor, 2003; Wills & Holmes-Rovner, 2006). Decision-making 
processes are influenced by multidimensional activities that can include cognitive, 
perceptual, and affective, factors and are defined as “the interactions of patient and 
contextual factors that are set in motion by the unique features of the decision problem” 
(Pierce & Hicks, 2001, p. 270). Patient decision-making can be influenced by a variety of 
factors such as health status, misinformation, emotions, and past experiences (Benbassat 
et al., 1998; Redelmeier, Rozin, Kahneman, 1993; Wills & Holmes-Rovner, 2006). The 
patient goes through a decision-making process to come up with a solution to a particular 
problem. Decision problems are the “representations of relevant information that must be 
considered in selecting a preferred alternative” (Pierce & Hicks, 2001, p. 270).  
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Patient Treatment Decision-Making in Substance Abuse 
Current substance abuse research suggests that individuals make an initial choice, 
or decision, about substance abuse behaviors. Over time, substance abuse behaviors 
become self-perpetuating and share similar patterns with other addictive behaviors such 
as gambling, sexual compulsions, and overeating (Miller & Carroll, 2006). Drug abuse 
has been described as a biological disorder that can range from impulsivity to 
compulsiveness, and the behaviors associated with drug abuse (such as self-injecting) can 
cause rewards such as pleasure, gratification, and relief of anxiety or stress (Koob, 2006). 
As the individual moves to addiction and with persistent drug abuse, he/she can lose 
decision-making control from an imbalance in the neurochemical center of the brain 
(Bechara, 2005; Bechara & Damasio, 2001). Researchers continue to investigate what 
triggers initial and ongoing decision-making choices surrounding substance abuse 
(Bechara, Dolan, & Hindes, 2002). In addition, how decisions are made to use illicit 
substances and turn to injection drug use is an area of active research in neurobiology 
(Bechara, 2005; Bechara & Damasio, 2001; Bechara et al., 2002; Di Chiara & North, 
1992), psychology (Compton, Conway, Stinson, Colliver, & Grant, 2005), sociology 
(Diaz et al., 2001; Hall, Charlesbois, Hahn, Moss, & Bangsberg, 2004; Inciardi, Surratt, 
& Kurtz, 2006) and behavioral medicine (Friedman et al., 1999; Lane & Cherek, 2000; 
Lane, Cherek, Pietras, & Tcheremissine, 2004; Lynch, Roth, & Carroll, 2002; Lane, 
Yechiam, & Busemeyer, 2006). Findings from substance abuse and decision-making 
literature demonstrate that substance abusers have poor decision-making capabilities and 
tend to make self-destructive decisions (Grant, Contoreggi, & London, 2000; Jeste & 
Saks, 2006; McNeil, 1987). There are continued debates in the healthcare industry about 
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the decision-making capabilities of individuals with substance abuse disorders (Jeste & 
Saks, 2006). In addition, little is known about the substance abuse issues that may 
influence HCV treatment decisions among co-infected infected adults from their 
perspective (Fraenkel et al., 2005). 
Patient Treatment Decision-Making in HIV Mono-infected Adults 
While little is known about how substance abuse affects decisions in HCV 
treatment choices, there have been several studies (see Table 1) examining patient 
decision-making in the context of HIV treatment from the patient’s perspective (Kremer, 
Ironson, Schneiderman, & Hautzinger, 2006; Laws et al., 2000; Marelich, Johnson 
Roberts, Murphy, & Callari, 2002; Misener & Sowell, 1998). For example, a positive or 
negative relationship with the healthcare provider can influence treatment decisions 
(Laws et al., 2000; Misener & Sowell, 1998). For patients deciding not to take HAART, 
they noted that their providers did include them in the decision-making process (Misener 
& Sowell, 1998). However, many also reported a lack of trust in their provider and stated 
that, because of this distrust, they were not truthful with their provider about their 
adherence to the medication regimen (Laws et al., 2000; Misener & Sowell, 1998). Fear 
of side effects from HIV medications was another factor in patients’ decisions not to 
begin ART (Kremer et al., 2006; Misener & Sowell, 1998). In one study, patients also 
admitted that their active substance abuse caused them to miss or skip taking their 
antiretroviral medications because they were instead focused on acquiring and using 
cocaine or heroin (Laws et al., 2000). 
For patients with HIV infection who choose to take HAART, findings indicate 
that patients wanted to work as part of a team in joint decision-making; however they 
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also took an assertive role by telling the healthcare provider which medications they 
wanted to take (Marelich, Johnson Roberts, Murphy, & Callari, 2002). Patients 
considering ART also actively seek out information from other healthcare providers, 
journals, and the Internet to supplement their knowledge about the treatment. These 
findings suggest that some patients with HIV infection take an assertive role and desire 
more control over their healthcare decisions (Kremer et al., 2006; Marelich et al., 2002). 
Understanding a patient’s thought process in decision-making may assist healthcare 
providers in guiding patients through treatment decisions. 
Patient Treatment Decision-Making in HCV Mono-infected Adults 
Because only one study was found on HCV patient treatment decision-making 
(see Table 2), (Fraenkel et al., 2005), there is limited information about how adults with 
HCV mono-infection make HCV treatment decisions. These investigators used focus 
groups to examine factors that influence patient decisions about HCV treatment. The 
sample (N = 40) consisted of mostly white (82%), employed (55%), men (80%) from two 
sites in Connecticut with a mean age of 51.5 (range 40-60). Separate focus groups were 
conducted with those who had a diagnosis of mental illness, and/or substance abuse, and 
those who did not have either comorbidity. The authors did not report the different 
outcomes between the two groups. However, the results offered six themes including 
treatment risks, benefits and tradeoffs, protected values, heuristics, conceptualization of 
illness, social issues, and physician recommendations. The patients wanted to know what 
their choices were, expected response rates, treatment side effects, the possibility of 
regretting treatment if the treatment failed, how sick they may be or become, how the 
therapy would affect work and family, and finally, what the physician recommended. The 
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authors concluded that healthcare providers should help facilitate patient decision-making 
through education. Also, healthcare providers should understand that the decision-making 
process may be influenced by their recommendations. This study offers some preliminary 
understanding of decision-making processes within a fairly specific group of individuals 
with HCV infection. Additionally, more work is needed to understand HCV treatment 
decision-making within various populations. 
Patient Treatment Decision-Making in HIV/HCV Co-infected Adults 
A patient’s decision to begin HCV treatment is not straightforward. HCV 
evaluation and treatment involves a significant amount of time, energy, effort, and 
compliance on the part of the patient. There is limited information on how adults with 
HCV mono-infection make decisions about HCV evaluation and treatment (Fraenkel et 
al., 2005). Even less is known about how adults with HIV/HCV co-infection with a 
history of substance abuse make treatment decisions. No research studies have focused 
on HCV treatment decision-making in adults co-infected with HIV/HCV and who have a 
substance abuse history. This gap in the literature prevents healthcare providers from 
understanding the influence of substance abuses on decision-making in the HIV/HCV co-
infected adult. 
Chapter Summary 
HCV infection affects between 150,000 to 300,000 HIV positive adults in the US 
(Alter et al., 1999; Sherman et al., 2002). Unfortunately, HCV treatment rates remain low 
in HIV/HCV co-infected patients. There is some evidence that patients face a variety of 
structural, personal, and social barriers when faced with the possibility of needing HCV 
treatment. However, there is limited knowledge about how these barriers affect decision-
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making in adults with HIV/HCV co-infection. In addition, there is little information about 
the influence of substance abuse on HCV treatment decision-making. Therefore, this 
study examined substance abuse experiences in adults with HIV/HCV co-infection and 
explored the experience of substance abuse as it relates to patient decision-making about 
HCV treatment. 
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Chapter II 
Organizing Framework 
Introduction 
The Interactive Decision-Making Framework by Pierce and Hicks (2001) was 
used to guide the data analysis section of the proposed study (See Figure 1). An 
organizing framework provides a foundation and guidance for a qualitative research 
study (Patton, 2002). This framework served as a general guide to organize the data 
analysis. However, the researcher was open to additional ideas or emerging themes 
outside any a priori beliefs or the organizing framework (Lincoln & Guba, 1985). Miles 
and Huberman (1994) suggest a framework should be used to structure the qualitative 
research study to provide a foundation for collecting and evaluating data. The structured 
qualitative project provides the researcher the opportunity to assess for patterns across the 
data set related to key concepts rather than just developing random thematic codes (Miles 
& Huberman, 1994). Also, some structure helps to prevent data overload which is caused 
by collecting large amounts of data with little organization and then not having the ability 
to sort out the important findings (Miles & Huberman, 1994). However, being open and 
observant to themes and codes outside the framework is an important skill for a 
qualitative researcher (Miles & Huberman, 1994). The purpose of the proposed 
qualitative descriptive study was to describe the substance abuse experiences in adults co-
infected with HIV and HCV. In addition, the experiences of substance abuse as it relates 
to patient decision-making about HCV treatment were explored. A secondary aim of this 
study was to explore whether substance abuse experiences fit best with patient or 
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contextual factors within the framework. This chapter focuses on understanding the 
Interactive Decision-Making Framework (Pierce & Hicks, 2001). 
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Figure 1. Organizing Framework for the Influence of Substance Abuse on Hepatitis C 
Treatment Decision-Making among HIV/HCV Co-infected Adults 
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Interactive Decision-Making Framework 
Patients are routinely asked to make decisions about their health care (Pierce & 
Hicks, 2001) and many of these decisions involve understanding complex therapies and 
treatments which can lead to stress and anxiety (Pierce, 1996). The decision-making 
process may be easy for some and difficult for others (Pierce, 1996). Researchers are 
beginning to explore decision-making processes and factors that influence patient choices 
(Fraenkel et al., 2005; Manias, Botti, & Buchnall, 2006; Pierce, 1993; Pierce, 1996; 
Redelmeirer, Rozin, & Kahneman, 1993). Moreover, there is limited research examining 
the decision-making process in patients faced with complex and stressful decisions 
(Pierce & Hicks, 2001). 
Defining Characteristics of the Framework 
Pierce and Hicks (2001) outline a decision-making framework to guide 
researchers investigating patient decision-making processes. The decision-making 
framework is deductive in nature and has three central concepts (See Figure 1). These 
concepts include the decision problem (alternative/choices, complexity, probability, 
outcomes), the patient (values/utilities, decision styles, preferences for participation, 
expectations, psychological state, physical state, and risk perceptions), and contextual 
factors (risk, urgency, patient-provider interaction, cognitive demands, environmental 
stressors, time frame, information). 
Decision Processes and Problems 
Patient decision-making is considered a process (Hicks & Holm, 2003; Noone, 
2002; Pierce & Hicks, 2001; Theroux & Taylor, 2003; Wills & Holmes-Rovner, 2006). 
Decision-making processes are complex cognitive, perceptual, and affective 
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multidimensional activities and are “the interactions of patient and contextual factors that 
are set in motion by the unique features of the decision problem” (Pierce & Hicks, 2001, 
p. 270). The patient goes through a decision-making process to come up with a solution 
to a particular problem. Decision problems are the “representations of relevant 
information that must be considered in selecting a preferred alternative” (Pierce & Hicks, 
2001, p. 270). The decision problem has four basic elements: initial options (alternatives 
or choices), values (worth, utility, or attractiveness), uncertainties (probabilities) and 
possible consequences (outcomes). The decision-making process is influenced by the 
interactions between patient factors and the contextual factors. There is a codependent 
relationship between the patient and the contextual factors and the relationship between 
these factors are constantly evolving depending on the decision problem. For example, as 
the patient gains more experience with the illness or disease process the stress of the 
decision may be diminished (Pierce & Hicks, 2001). 
Patient Factors 
There are a variety of patient factors that influence the decision-making process. 
The decision-making processes can be influenced by personal characteristics such as 
values, decisions styles, preferences, expectations, physical and psychological health, and 
perception of risk (Pierce & Hicks, 2001). Patient’s decision-making behaviors can 
evolve or adapt depending on the context of the patient’s personal experiences (Pierce & 
Hicks, 2001). For example a patient may be hesitant and fearful about hemodialysis 
treatment due to personal and cultural beliefs but, may be forced to accept treatment or 
face death (Lin et al., 2005). 
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Contextual Factors 
Contextual factors may influence the decision-making processes include: risk, 
urgency of the problem, patient-provider interaction, cognitive demands, environmental 
stressors, time frame, and information (Pierce & Hicks, 2001). For example, the decision 
can be influenced by the urgency of the problem or by how much information the patient 
has to make the decision (contextual factors). 
The decision-making process is influenced by the codependent relationship 
between the patient and contextual factors. For example a patient may have made specific 
decisions (patient factors) about their health care and those preferences change because 
they were not supported in their choice or they lacked information to make an informed 
decision (contextual factors) (Carlton, Callister, & Stoneman, 2005). 
Use of the Framework in Research 
The interactive decision-making framework has been used to study patients’ 
decision-making processes regarding hemodialysis treatment among (1) Taiwanese adults 
(Lin et al., 2005), (2) in women during labor (Carlton et al., 2005), and (3) women with 
breast cancer (Budden, Pierce, Hayes, & Buettner, (2003). The interactive decision-
making framework has also been used to guide the development of a heart failure self-
management tool (Hicks & Holmes, 2003).  
Decision-making styles vary among patients and personal values influence 
decisions (Budden et al., 2003; Carlton et al., 2005; Lin et al., 2005). Patients also want 
to have a choice and be in control of their health care decisions (Budden et al., 2003; 
Carlton et al., 2005). As part of maintaining a sense of control, many patients seek out 
information from family, friends, internet resources, and other healthcare providers 
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before making decisions (Budden et al., 2003; Hicks & Holm, 2003; Lin et al., 2005).  
Patients can be fearful of treatments which can delay important decisions about their 
health care (Lin et al., 2005).  
Carlton and colleagues (2005) found women went into labor with certain planned 
preferences. However, their decisions changed because of contextual factors such as lack 
of support by nurses or healthcare providers, lack of alternative strategies for pain 
management, lack of education on birthing strategies, or because of emotions such as 
guilt. Hick and Holms (2003) found patients tended to make fewer decisions as their 
disease advanced.  
Currently, a decision-making theory or empirical model has not been generated 
from this framework. There are no published studies using this framework examining 
patient decision-making behaviors surrounding substance abuse or HCV treatment.  
Chapter Summary 
Patients with HIV/HCV co-infection must make decisions about HCV treatment 
in which they may experience significant side effects, and a relatively high likelihood of 
treatment failure. Limited knowledge exists on how patients make decisions about HCV 
treatment. In addition, it is unclear how patients with substance abuse disorders and co-
infection make decisions about HCV treatment. Finally, it is unclear where substance 
abuse fits in the interactive decision-making framework. A secondary aim of this study 
was to uncover the “best fit” for substance abuse within the framework. It is possible that 
substance abuse may fit in either category (patient or contextual), however there may be 
an unknown intermediary category to the framework that is not yet known. The 
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researcher was open to any emerging possibilities and report the findings. Specifically 
this framework was used to address the following questions: 
• What are the substance abuse experiences in adults co-infected with HIV 
and HCV infections? and, 
• How does the experience of substance abuse influence patient decision-
making about HCV treatment? 
The answers to these questions may improve our understanding about substance 
abuse experiences in individuals with HIV/HCV co-infection and add to our knowledge 
about how these experiences influence HCV treatment decisions. Knowledge gained may 
lead to the development of interventions to support HIV/HCV co-infected patients with 
substance abuse problems during the HCV treatment decision-making process. 
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Definitions and Specific Aims 
For the purpose of this study the following definitions were used: 
• Substance abuse is defined as problematic use (self-identified by study 
participants) of alcohol and drugs (prescription or street drugs). 
• Decision-making processes are the interactions of patient and contextual 
factors that are set in motion by the unique features of the decision 
problem (Pierce & Hicks, 2001). 
The specific aims of this study were to: 
• Describe substance abuse experiences in adults co-infected with HIV and 
HCV and, 
• Explore the experience of substance abuse as it relates to patient decision-
making (including the decision problem, patient, and contextual factors) 
about HCV treatment. 
A secondary aim of this study was to: 
• Explore whether substance abuse experiences fit best with patient or 
contextual factors within the Interactive Decision-Making Framework 
(Pierce & Hicks, 2001). 
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Chapter III 
Methods 
Introduction 
The proposed study used qualitative description and secondary data analysis to 
describe substance abuse experiences of adults with HIV/HCV co-infection. In addition, 
how these experiences were related to patient decision-making about HCV treatment was 
examined. A secondary aim was to explore whether substance abuse experiences fit with 
patient or contextual factors within the framework Interactive Decision-Making 
Framework (Pierce & Hicks, 2001). The Interactive Decision-Making Framework (Pierce 
& Hicks, 2001) was used to guide the secondary data analysis and summary of findings 
(see organizing framework, Figure 1). The pre-existing data set was collected as part of a 
longitudinal multi-method study (NIH #1R15 NR0834) aimed at describing the 
experiences of HCV treatment among HIV seropositive adults. 
The purpose of this chapter is to describe the methods used in this study. 
Qualitative descriptive methodology and rationale, epistemological, ontological and 
theoretical underpinnings, the process of secondary data analysis, and description of the 
parent study will be delineated. The sample, procedures for data collection and 
management, data analysis, trustworthiness, ethical considerations, human subject 
considerations, and limitations are described for the research study.  
Qualitative Descriptive Methodology and Rationale 
Qualitative descriptive design was chosen as the method of inquiry for the 
proposed study to describe substance abuse experiences. In addition, how these 
experiences impact patient decision-making regarding HCV treatment in adults with HIV 
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and HCV co-infection were explored. The qualitative methodology allowed the 
researcher to gain insight into the phenomenon of interest by exploring the day-to-day 
experiences of the participants, develop a rapport with the participants, and to stay close 
to the data without an in-depth deconstruction and reconstruction of the findings (Gallo & 
Dumas, & Shurpin, 1996; Knafl & Howard, 1984; Miles & Huberman, 1994; Sullivan-
Bolyai, Bova, & Harper, 2005). Qualitative description is a method that allows the 
researcher to describe the phenomenon of interest with minimal interpretation of data 
(Sandelowski, 2000). A key benefit of the methodology is the ability to obtain an in-
depth subjective view into HIV/HCV co-infected participants’ experiences. Qualitative 
description was used to provide a preliminary understanding of this scarcely researched 
phenomenon (Sandelowski, 1999). 
Epistemological/Ontological/Theoretical Underpinnings 
Epistemologically, the naturalistic paradigm fits well to explore subjective 
substance abuse experiences in adults with HIV and HCV infection. The researcher 
becomes a research instrument who can interact with the subject of inquiry (Lincoln & 
Guba, 1985). The researcher for the proposed study was the research assistant for the 
parent study. This involvement afforded the researcher a working knowledge of the 
parent study. However, the researcher is aware that all inquiry is value-laden, to some 
extent. Personal views and a priori assumptions of the subject matter were bracketed 
(Marshall & Rossman, 1999). A reflexive journal was maintained throughout the analysis 
process to document the research process. Ideas, assumptions, and a priori beliefs were 
documented (Ahern, 1999). In addition, for this study, the researcher bracketed 
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preconceived ideas about the personal biographies of the participants. Further, the journal 
was available to the dissertation committee throughout the study.  
Ontologically, reality and the meaning of the experience come from the subjective 
perspective; this can only come from the individual living the experience. The meaning 
was derived and presented by using quotes and developing themes based on the stories of 
the participants (Creswell, 1998). 
Theoretically, the Interactive Decision-Making Framework (Pierce & Hicks, 
2001) was used to guide secondary data analysis. The framework provided the initial 
structure for the data analysis; however, it did not limit the findings. The researcher was 
open to themes that emerged outside of the framework as they related to the research 
questions. Major themes and sub-themes were identified and are described in the 
findings. 
Process of Secondary Data Analysis 
The study used secondary data analysis (SDA) to investigate the pre-existing data 
set. SDA is a research technique used to “generate new knowledge from existing data” 
(Magee, Lee, Giulano, & Munro, 2006). SDA is a research technique used to examine 
pre-existing data based on a new set of questions; it can also be used for a more focused 
analysis of the parent study (Castle, 2003; Heaton, 1998; Heaton, 2004; Hinds, Vogel, & 
Clarke-Steffen, 1997; Szabo & Strang, 1997). Quantitative data has typically been used 
for SDA, however the use of pre-existing qualitative data sets is growing (Heaton, 2004). 
There are several advantages to SDA, including a shorter time in answering 
research questions. Using pre-existing data also saves the expense of primary data 
collection (Heaton, 1998; Heaton, 2004; Rew, Koniak-Griffin, Lewis, Miles, O’Sullivan, 
44 
2000; Shepard et al., 1999). SDA provides the researcher the opportunity to access 
difficult populations or those who may be over-sampled due to the uniqueness of their 
condition (Kiecolt & Nathan, 1985). Moreover, burden to study participants is reduced, 
especially in vulnerable or hard-to-reach persons by using an existing data set (Heaton, 
1998). This was an important consideration in this research study. The participants of the 
parent study are co-infected with HIV and HCV and may be suffering from a variety of 
disease symptoms and side effects of medications and treatments. Participating in an 
additional study may have placed an added burden on them. Furthermore, SDA can be 
used to explore information which was not part of the original question (Hinds, Vogel, & 
Clark-Steffen, 1997). Many of the participants in the parent study disclosed information 
about their substance abuse history that went beyond the scope of the initial investigation. 
These data emerged spontaneously and the participants were allowed to freely express 
their substance abuse experiences. The principal investigator (PI) of the parent study 
decided that these data should be analyzed and reported. It was important to represent and 
respect the participants of the original study by reporting the additional findings. The 
information provided by participants may serve others in their quest for additional 
understanding of substance abuse experiences and HCV treatment decision-making in 
adults with HIV and HCV co-infection. 
Moreover, the researcher using secondary data analysis may provide objectivity 
and neutrality (Heaton, 2004). At the time of the parent study, the researcher of the 
proposed study was not working with this patient population, thus allowing for 
objectivity and neutrality during the interviews. In addition, this strength can transfer to 
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the data analysis. The data set was analyzed objectively without preconceived biases 
about individuals with HIV/HCV co-infection and substance abuse problems. 
Disadvantages of SDA include the fact that the parent study may be grounded 
from a different philosophical or theoretical perspective (Rew et al., 2000); there may be 
missing data without the possibility of further data collection; lack of face-to-face contact 
with participants; and there may be issues with sensitivity (Hinds et al., 1997). For the 
context of the research study, each of these issues will be addressed in the following 
paragraphs. 
From a philosophical and theoretical perspective, the researcher of the parent 
study sought to reveal the subjective experiences in adults with HIV and HCV co-
infection. The organizing framework of the parent study was based on health related 
quality of life, symptom/side effects, treatment adherence, mental health issues, and 
substance abuse issues. In the proposed study, the Interactive Decision-Making 
Framework (Pierce & Hicks, 2001) was used to guide the secondary data analysis. The 
framework is multifaceted and deductive in nature. The purpose of the framework was to 
provide insight into the phenomenon of interest through the literature and to assist in the 
organizing and representation of the data (Sandelowski, 1993). The framework allowed 
the researcher to explore subjective experiences of HCV treatment without limiting the 
participants’ responses. The researcher used the framework to guide the analysis and gain 
control over the volume of data, however, the framework did not limit the findings. 
Alternative findings were explored within the data set and reported in the discussion. 
Lack of face-to-face contact with participants has been identified as a 
disadvantage to SDA (Heaton, 1998; Hinds et al., 1997). The secondary researcher does 
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not have the opportunity to “be there” to be immersed within the data collection. 
However, the secondary researcher can become immersed within the data without the risk 
of biases and preconceived beliefs in order to develop new knowledge (Thorne, 1994). 
The researcher of the study listened to the tone, emotions, and inflections of the 
participants by listening to the audiotapes. The transcripts, field notes, and memos were 
read to become immersed within the data set which was done to enhance sensitivity. 
Sensitivity refers to how immersed or close the researcher can become in the data 
set in qualitative research (Hinds et al., 1997). This may be challenging in SDA of 
qualitative data since the researcher is considered an instrument of the investigation and 
immersed in the research process but was not there during data collection (Heaton, 1998; 
Hinds et al., 1997). The researcher of the study was involved in the data collection in the 
parent study and developed a rapport with the participants. In addition, the researcher was 
involved in meetings and discussions and dissemination of results of a pilot study and 
original study data at the Eastern Nursing Research Society Meeting in 2004. By being 
involved in the parent study is different from that of someone looking at the data for the 
first time (Thorne, 1994). 
Description of Parent Study 
The parent study was an NIH funded (1R15 NR0834) longitudinal multi-method 
study to describe the experiences of HCV treatment among HIV seropositive adults 
conducted by Dr. Carol Bova from the University of Massachusetts, Worcester. The 
setting for the parent study took place at three HIV specialty clinics. Approval for the 
parent study was obtained from the Institutional Review Board (IRB) of University of 
Massachusetts, Worcester Medical School. IRB approved recruitment flyers were 
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distributed at the approved clinical sites. The participants were instructed to call a 
designated phone number and leave contact information if they were interested in 
participating in the research study. The PI or the research assistant (RA) called the 
prospective participant back to discuss the objectives of the study, answer questions, and 
set up an interview. The participants were told their involvement in the study was 
voluntary, they could withdraw from the study at any time, and participation or lack of 
participation would not influence their care in any way. Informed written consent and 
HIPAA authorization was obtained prior to the interview. The participants received 
$25.00 for their participation in the parent study. A signed original copy of the consent 
was given to the participant and a copy was retained in the study files. The participants 
were assigned a study number to protect anonymity and confidentiality. The study 
number is on each data form, audiotape, and transcription to keep the data organized. The 
participant’s name was not used on any data form, audiotape, or transcription. The PI 
maintained the list of participants and their assigned study numbers. 
Description of Parent Study Data Collection and Measures 
The data were collected by the PI or the RA by face-to-face semi-structured 
interviews. The researchers used the Parent Study Interview Guide (Appendix A) to 
conduct the qualitative interview. The interviews were audiotaped, and then transcribed 
verbatim by a profession transcriptionist. Additional data collected during the parent 
study included the Parent Study Demographic Data and Clinical Cofactor Sheet 
(Appendix B), the Parent Study Alcohol and Drug Dependency Questionnaire (Appendix 
C), and the Parent Study Mental Health Questionnaire (Appendix D). 
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The Parent Study Qualitative Interview Guide (Appendix A) was used to provide 
a general direction to the in-depth baseline interview to explore patient experiences of 
living with HIV/HCV co-infection. The interview guide was used to direct the open-
ended questions about symptoms of HCV, problems with mental health, drugs and 
alcohol problems, and how the heath care provider could help the patient manage HCV 
before beginning treatment. Probes were structured to illicit more specific information 
about their personal reactions to their diagnosis, emotional feelings about living with 
HCV, current and past problems with substance abuse, and the usefulness of the 
information that was given to them by their healthcare provider. 
The Parent Study HIV/HCV Co-infection Baseline Demographic and Clinical 
Cofactor Sheet (Appendix B) was a self-report measure that included the participant’s 
age, gender, race, ethnicity, education, work status, marital/partner status, housing status, 
length of time with HIV, substance abuse history. Clinical cofactors were collected by 
medical record review via the clinical database that included the patient’s HIV illness 
stage, current HAART treatment, HIV RNA, HCV RNA, HCV subtype, and liver biopsy 
results. 
The Parent Study Alcohol and Drug Dependency Baseline Questionnaire 
(Appendix C) was a self-report measure that was used to ascertain the participant’s 
current and past substance abuse, which substances they used, the last time they used 
substances, and what was their most problematic substance. 
The Parent Study Mental Health Questionnaire (Appendix D) was a self-report 
measure that was used to determine the participant’s current and past mental health 
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problems, hospitalizations to treat depression/mood problems, current medication to treat 
mental health/mood problems, and any history of suicide attempts. 
Description of Parent Study Participants 
The participants in the parent study were recruited by purposive and theoretical 
sampling techniques. The sample size was determined by theoretical saturation which is 
the point when no new properties or dimensions emerge from the data and the analysis 
accounts for as much variation as possible (Stauss & Corbin, 1998). The sample included 
39 HIV/HCV co-infected adults (16 in the treated cohort and 23 in the non-treated 
cohort), 48% were female, 52 % were male, 54% were racial or ethnic minorities, 33% 
AIDS, 73% had HCV genotype 1 and 95% had a history of substance abuse. The mean 
age was 44.7 years. Inclusion criteria for the parent study were: (1) age 18 years of age or 
older, (2) HIV/HCV co-infected (detectable HCV viral load and HIV positive antibody 
test or viral load documented in medical records), (3) not yet on HCV treatment, and (4) 
able to speak English. Forty participants were initially recruited into the study. However, 
one participant was excluded from the analysis because she was later found not to be HIV 
positive.  
Proposed Research Study 
Sample for Proposed Study 
Sampling in secondary data analysis in a qualitative study has been considered 
sorting of data (Heaton, 2004). The researcher sorts through the parent study to determine 
the sub-sample for the secondary data analysis (Heaton, 2004). Through sorting, the 
parent sample should be assessed to determine if there will be a sufficient sample size 
available to answer the new research questions (Heaton, 2004; Thorne, 1994). The PI of 
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the parent study determined there would be adequate information available for the 
secondary data analysis as she completed her examination of the data set. Sandelowski 
(1995) has suggested that different qualitative approaches require different sample sizes. 
Sample size depends on the purpose of the qualitative study and what the researcher 
wants to know which may be more important than an actual number of participants 
(Patton, 2002; Sandelowski, 1995). Morse (1994) suggests at least six participants are 
needed in studies directed toward discerning the essence of experiences. Quality versus 
quantity may be more important when establishing a sample in a qualitative study 
(Patton, 2002). The interviews should contain specific in-depth information pertaining to 
substance abuse experiences and HCV treatment decision-making and only the interviews 
that contain this information were used for the analysis. It was estimated that 
approximately 25 (64%) of the 39 interviews would be used for the secondary data 
analysis (Morse, 1994). The researcher used the Secondary Data Inclusion/Exclusion 
Extraction Criteria Tool (Appendix F) to review each interview. Inclusion criteria for the 
proposed study: (1) only baseline interviews from the longitudinal data set; (2) current or 
past injection drug abuse and/or alcohol substance abuse; and (3) interviews containing 
rich descriptive information about substance abuse experiences and decision-making 
information. 
The researcher evaluated the quality of the interview to determine if it contained 
enough information to be considered part of the sample. If the interview contained the 
required information, it was included into the analysis. If the individual interview did not 
contain enough information to answer the research questions, the researcher consulted 
with the dissertation chairperson. A meeting was scheduled to assess each interview that 
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did not meet the inclusion criteria. The dissertation chairperson member read through the 
interviews in questions to determine if it met the inclusion criteria (Appendix F). Notes 
were compared by the team members and a collaborative decision was made about the 
inclusion or exclusion of the transcript. All notes about the excluded interviews were 
documented in the journal for the audit trail. The final interviews and sample size was 
verified by the dissertation chairperson. The final sample included 31 interviews.  
A total of eight interviews (six men and two women) were excluded from the 
secondary data analysis. Interviews were excluded for the following reasons: the 
participant spoke mostly Spanish and did not understand the questions presented (n = 1), 
no history of substance abuse (n = 2), the interview tape was blank (n = 1), blaming 
dentist for HIV/HCV co-infection rather than injection drug abuse (n = 1), and responses 
contained only yes/no answers (n = 3). 
Procedures for Proposed Study 
Data Collection and Management for Proposed Study  
The researcher obtained the data set from the PI of the parent study after the 
proposal was approved by the dissertation committee members. The PI transferred the 
electronic version of the transcripts onto a password protected universal serial bus (USB) 
thumb drive. The data were checked to ensure all of the components were accounted for 
(Appendix E). 
The interviews have been transcribed previously and were available in individual 
coded electronic Microsoft Word documents. After receiving the data set, the researcher 
listened to audiotapes and read the transcripts to ensure accuracy (Sandelowski, 1995). 
The plan was to note the discrepancies between the audiotape and transcripts and discuss 
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these findings with the PI however, there were no discrepancies to discuss. The 
demographic data were checked by comparing the hard copy of each participant with the 
transcription. Missing data from the qualitative and demographic measures were 
assessed. Again the plan was to note any patterns in missing data and discuss these 
patterns with the PI. There were a few missing data points, however, no patterns existed 
in the data set.  
The data set was stored in a locked file cabinet in the researcher’s office 
throughout the data analysis. In addition, the electronic data were stored on a password 
protected USB thumb drive and computer hard drive. All of the electronic data were 
deleted from the thumb drive and computer hard drive and the entire data set was 
returned to the PI at the conclusion of the study. All of the printed interviews were 
mechanically shredded at the end of the study. 
Data Analysis 
Data Analysis Plan 
The researcher used qualitative content analysis to examine the data. Qualitative 
content analysis uses a systematic format to develop codes, or labels, to describe data 
from careful reading of the interview transcripts (Knafl & Webster, 1988; Morgan, 1993).  
NVivo software was used to manage and organize the qualitative data (QRS 
International, 2007). Initially, the researcher transferred the Microsoft word transcripts 
from the USB thumb drive into the NVivo software program. Then, the transcripts were 
printed. The researcher then read through the transcripts and listened to the audiotapes to 
ensure the accuracy of the transcripts. Initial impressions of the interview were noted in 
the reflexive journal. A codebook was created to list, organize, and arrange codes and 
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data according to predetermined criteria. The purpose of coding is to cluster large pieces 
of data into a smaller number of focused descriptive themes (Miles & Huberman, 1994; 
Morgan, 1993). Codes were consolidated where possible, and ongoing attempts were 
made to compare and contrast patterns within and across data (Creswell, 2003). Some of 
the codes referred back to the organizing framework; others emerged spontaneously 
during analysis (Sandelowski, 2000).   
Responses related to the specific research questions and the framework were 
identified and coded during the first pass analysis. Initial codes were documented in the 
reflexive journal and discussed with the dissertation chairperson. The codes were cut and 
pasted into a Microsoft Word document data display (Glaser & Strauss, 1967; Miles & 
Huberman, 1994; Webb, 1999). The data display listed each participant and the raw data 
pertaining to each research question according to the Secondary Data Extraction Tool 
(Appendix G) (Miles & Huberman, 1994; Williamson, 2005). The same process took 
place for each transcription. The frequencies of the responses were counted and were 
used as part of the description of the patterns within the data (Sandelowski, 2000). Codes 
were consolidated when possible, and ongoing attempts were made to compare and 
contrast patterns within and across data (Creswell, 2003).  The purpose of qualitative 
content analysis was not to develop exclusive categories, but to develop salient points 
from the data (Marshall & Rossman, 1999; Sandelowski, 2000). Minimal interpretation 
allowed the experience to be portrayed as it was described by participants. 
Data Re-Presentation 
Finally, the categories and themes were reconstructed into a meaningful 
description of the experiences of the participants (Knafl & Howard, 1984; Sandelowski, 
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2000). Descriptive statistics in SPSS for Windows 14.0 were computed for all 
demographic and clinical cofactors to describe the sample characteristics. The results, 
sample demographics and clinical cofactors were displayed in written format as well as in 
tables. 
Trustworthiness 
Establishing rigor or trustworthiness in qualitative research is based on four 
components: transferability, dependability, credibility, and confirmability (Lincoln & 
Guba, 1985). Transferability or fittingness is a form of external validity that is 
constructed in qualitative research projects (Morse & Singleton, 2001; Rolfe, 2006). 
Ensuring the phenomenon of interest fits with the research questions and methods is an 
element of validity construction (Morse & Singleton, 2001; Whittemore, Chase, & 
Mandle, 2001). Fittingness was accomplished by constructing descriptions of the 
experiences of the participants and summarizing the overall observations of the data. Fit 
has occurred if the researcher can describe how the clusters of data are part of the whole 
(Morse & Singleton, 2001). The reconstructed themes can be traced back to the original 
data by the use of direct quotes from the participants. The dissertation chairperson 
reviewed the themes and codes as they emerged from the data set to ensure transferability 
and fit. Dependability refers to the consistency and authenticity of the research process 
(Koch, 1994; Lincoln & Guba, 1985). A reflexive journal was maintained by the 
researcher and included personal reflections, biases, field notes, bracketing notes, 
methodological issues, and any decisions made during the research process (Ahern, 
1999). The researcher retained a copy of all written or electronic correspondence that 
pertained to the research project. The journal was made available to the dissertation 
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committee throughout the research process. These tasks served as the audit trail and 
dependability was verified by an audit of the research process. Credibility refers to the 
overall quality of the research and accurate representation of the data and internal validity 
(Lincoln & Guba, 1985; Whittemore et al., 2001; Creswell, 1998). Developing credibility 
took place by maintaining a personal journal, and peer debriefing. Peer debriefing took 
place by constant contact with the dissertation committee. Peer debriefing was 
accomplished through phone, email, and face-to-face meetings throughout the entire 
study. 
Confirmability refers to the degree in which the results can be corroborated by 
others through documentation or audit trail. The dissertation committee audited the study 
process. The audit process was also used to ensure biases were not introduced into the 
findings. 
Human Subjects Considerations 
IRB approval was obtained for the parent study from the University of 
Massachusetts, Worcester Medical School and continued re-approval was obtained to 
extend the study timeline which is maintained by the PI of the parent study. There were 
no anticipated psychological or physical risks to the participants as the data have been 
previously collected. A major concern was that the data were analyzed and made 
available, as the participants freely spoke about their substance abuse history and 
personal life stories. The consent from the parent study allows the researcher to contact 
participants every three months for up to two years after the completion of the parent 
study which will be in June of 2007. Two participants from the parent study will be 
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contacted for member checks. The researcher of this study did not have access to names, 
addresses, or contact information of the participants. 
Ethical Considerations for Proposed Study 
After the data set was obtained from the principal investigator, it was stored in a 
locked file cabinet in the investigator’s office. Any electronic data were stored on a 
password protected USB thumb drive and computer hard drive. All of the electronic data 
were deleted off of the USB thumb drive and computer hard drive and the entire data set 
was returned to the PI at the conclusion of this study. Any printed material was 
mechanically shredded at the conclusion of the study. 
The participants were assigned a study number to protect confidentiality in the 
parent study and the same number was used in this study. The list of names was not 
transferred to the researcher of this study. The researcher of this study did not have access 
to names, addresses, or contact information of the participants. 
Limitations 
A limitation of this study was the use of secondary data analysis. The data set 
contained a finite amount of information. The researcher of this study did not ask the 
participants to provide additional information. Secondly, it was anticipated that the 
sample size may not be adequate to reach saturation due to the number of participants in 
the parent study. However, the PI found that many of the interviews contained rich 
descriptive content pertaining to substance abuse experiences and HCV treatment 
decision-making issues. It was estimated that approximately 25 of the interviews could be 
included in the proposed study. Thirty-one interviews were included in the final sample 
for the secondary data analysis. Lastly, the participants of the parent sample were 
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recruited through purposive and theoretical sampling techniques limiting the sample to 
those with HIV/HCV co-infection. It is unknown if the individuals who volunteered for 
the parent study would have similar experiences as those who did not participate. 
Chapter Summary 
This study used a qualitative descriptive design and secondary data analysis to 
describe substance abuse experiences and explore the experiences of substance abuse as it 
related to patient decision-making about HCV treatment in HIV/HCV co-infected adults. 
The Interactive Decision-Making Framework (Pierce & Hicks, 2001) was used to guide 
secondary data analysis and summary of findings. Through secondary data analysis and 
qualitative content analysis, the researcher organized, summarized, and reported common 
themes related to the phenomena of interest. The results of this study will enhance the 
knowledge about substance abuse experiences in adults with HIV/HCV co-infection. 
Moreover, the findings of this study may help researchers and clinicians design and study 
strategies that address substance abuse issues related to HCV treatment decision-making. 
Finally, the information gleaned from this study may aid healthcare providers in assisting 
the patient in their decisions about HCV evaluation and treatment. 
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Chapter IV 
Results 
Introduction 
Qualitative description and secondary data analysis were used to describe the 
substance abuse experiences of adults with HIV/HCV co-infection. Additionally, how 
these experiences were related to patient decision-making about HCV treatment was 
examined. A secondary aim explored whether substance abuse experiences fit with 
patient or contextual factors within the Interactive Decision-Making Framework (Pierce 
& Hicks, 2001). The data were analyzed across and within subjects and the results were 
organized by each study aim. Next, qualitative content analysis was completed on 31 
interviews. NVivo 7 (QRS International, 2007) software was used to help manage the 
data during the coding process. SPSS was used to manage the demographic and clinical 
characteristic data. Some themes emerged spontaneously during the analysis while others 
were extracted based upon the research questions and the Interactive Decision-Making 
Framework (Pierce & Hicks, 2001). Information was removed from some quotes 
(indicated by brackets) to protect the anonymity of the individual participants. 
Five major themes with sub-themes emerged during the data analysis. They were: 
(1) Substance Abuse Evolution (with sub-themes: substance abuse initiation, escalation, 
polysubstance abuse, normalcy: a family of addicts, the enemy within, and transmission 
and disclosure), (2) Revolving Door: Going Back Out (with sub-themes: specific events 
as a trigger, emotions as a trigger, alcohol as a trigger, and destructive relationships as 
a trigger), (3) Reconstructing Life (with sub-themes: defining moments in substance 
abuse addiction and maintaining sobriety), (4) HCV Infection Treatment Issues (with 
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sub-themes: HCV treatment: not a priority, fear, and misinformation, desire to use 
stimulated during HCV treatment), and (5) Get Clean and Try It. A detailed description 
of the findings major themes, sub-themes, and a description of the secondary aim follow. 
The results are organized by each study aim. 
Participants 
Based on the Inclusion/Exclusion Criteria Form (Appendix F), 31 participants 
were selected from the parent study sample. This sample included 16 men (52%) and 15 
women (48%) with a mean age of 44.7 (range = 34-58). The majority of the participants 
were educated at the high school or GED level (71%), were not currently employed 
(68%), were single (52%), and were living in a rented apartment (55%). The racial 
breakdown for this sample was 58.% White, 26% Hispanic, 13% African American, and 
3% American Indian. In comparing men to women, men (M = 47) were older than 
women (M = 42) (x2 = 2.962, df = 27, p < .05). More women (n = 4) were marginally 
housed (homeless, shelter, or half-way house) compared to men (n = 0) (x2 4.9, df  = 1, p  
< .05). See Table 3 for the demographic characteristics of the sample. 
The participants had been living with HIV infection an average of 13.7 years 
(range = 2-20 years). Their CD4 cell counts ranged from 104 to 1056 (M = 468.5), 36% 
had AIDS, and 81% were on antiretroviral therapy to treat their HIV infection. There was 
no difference by gender in participants with a diagnosis of AIDS (p = .12).  
The HCV/RNA ranged from 550 to 18,900,000. Ten percent of the participants 
had an undetectable HCV/RNA, and a majority (61%) had undergone a diagnostic liver 
biopsy.  More men (n = 13) had a liver biopsy when compared to women (n = 6) (x2 = 
5.5, df = 1, p < .05). Ten (32%) of the participants had a history of previous HCV 
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treatment or were currently undergoing HCV treatment. The majority of the participants 
(76%) were infected with HCV genotype 1. See Table 4 for the complete clinical 
characteristics of the sample. 
All of the participants had a history of substance abuse with 87% identifying 
heroin as a frequently abused drug; cocaine followed with 84% reporting abuse, and then 
alcohol (77%). Twenty-nine (94%) of the participants reported problems with poly-
substance abuse (use of two or more substances in various combinations).  
During the interviews, the participants self-identified one to nine problematic 
substances. The largest group included nine participants who identified the same six 
problematic substances. These six substances were alcohol, heroin, cocaine, speedball, 
crack, and marijuana. See Tables 5, 6, and 7 for more information about the substance 
abuse characteristics of the sample. 
A majority (87%) of the participants reported having a diagnosis of mental illness 
at some point in their lives, with depression (67%) being the most frequent condition. Of 
those with mental illness, 65% were taking medications for their illness. Over a third of 
the participants (39%) reported prior suicide attempts, and 29% had been hospitalized to 
treat their mental illness. See Table 8 for the mental health characteristics of the sample. 
Four participants (13%)—one man and three women—voluntarily disclosed they 
had been in prison for possession of drugs, intent to distribute drugs, or distribution of 
drugs. 
Aim 1: Substance Abuse Experiences 
The participants spoke openly about their substance abuse experiences. However, 
it was difficult for them to separate their substance abuse experiences from HIV- or 
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HCV-related experiences. Therefore, when asked to describe what it was like living with 
HCV infection, nearly half (45%) of the participants began speaking about their 
substance abuse experiences instead. 
Three major themes with sub-themes emerged during the data analysis associated 
with substance abuse experiences. They were: (1) Substance Abuse Evolution (with sub-
themes: substance abuse initiation, escalation, polysubstance abuse, normalcy: a family 
of addicts, the enemy within, and transmission and disclosure), (2) Revolving Door: 
Going Back Out (with sub-themes: specific events as a trigger, emotions as a trigger, 
alcohol as a trigger, and destructive relationships as a trigger), and (3) Reconstructing 
Life (with sub-themes: defining moments in substance abuse addiction and maintaining 
sobriety). Data supporting each theme and sub-theme are presented below. 
Substance Abuse Evolution 
The evolution of substance abuse was the first major theme to emerge in data 
analysis. All of the participants had a history of substance abuse and there was a wide 
variety of responses describing how their substance abuse evolved. For example, some 
participants described how their substance abuse began, how their substance abuse 
escalated, and how they then abused multiple substances. For some, drugs and alcohol 
abuse in the home was a normal part of growing up and for others, there was something 
within themselves telling them it was okay to abuse drugs and alcohol. The participants 
discussed how their lifestyles and substance abuse led to HIV/HCV co-infection. Finally, 
some disclosed they were still struggling with substance abuse at the time of the 
interview. 
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Substance Abuse Initiation 
Fourteen (45%) participants said they were children or teenagers when they 
started drinking alcohol and/or abusing drugs. For example: 
• “I can remember I started injecting heroin at a very early age, age 13,” 
• “I started drinking alcohol as a teenager,” 
• “I started drinking around age eight or nine.”  
Another participant described feeling nervous as a young child saying “I always had 
anxiety attacks even when I was young. I started using heroin and stuff, it made me feel a 
lot better.” 
Nine of the 14 participants said they started drinking alcohol as children because 
it was available to them and from there they moved on to hard drugs. One woman said 
“My father was an alcoholic. I drank in school when I was a teenager. I then used 
[heroin] everyday when I got out of jail [for distribution of drugs].” One participant told 
the story of how he became involved with drugs and alcohol as a child:  
I started with alcohol at eight or nine because alcohol was always in the home. 
From alcohol, I graduated to marijuana. From marijuana, it was a mixture of 
anything you could get your hands on, acid to hallucinogenics. At 14, I picked up 
heroin and injected it. Nobody sniffed heroin back then. We used to inject it.... 
Then after that it led to the cocaine and to drinking and all kinds of other pills. 
Two women and one man disclosed they had been sexually, physically or 
emotionally abused as children by family members and turned to drugs and alcohol to 
cope. One of the women said: 
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I came from a very abusive family, sexually, emotionally and physically. I ran 
away at 16—got married at 17—had my first baby two months before I turned 18. 
My first husband was a user. There is not a drug addict that I know that doesn't 
want the other one they’re with not to be like them. Somebody always wants to 
pull you down. I got pulled down, started using. 
The second female participant recalled being physically and sexually abused by a 
male relative at around age 11 and as a result started hating herself. Then, she became 
involved with a man that introduced her to drugs by using and selling them. She said “I 
became involved in drugs around the age of 16 and I loved how the drugs made me feel.” 
She was in jail several times for using and distributing heroin. She is now taking her 
recovery and her return to health “one day at a time.” 
The male participant described the severe physical and sexual abuse and neglect 
he suffered as child. He turned to living on the streets and started using and selling drugs 
in shelters and in shooting gardens (abandoned buildings used for squatting and drug use) 
to earn money to live. 
Escalation 
Sixteen (52%) participants described how their substance abuse escalated. For 
some, their drug and alcohol consumption escalated over a period of years; for others it 
was very rapid. One participant said this about her substance abuse: “At first it was 
recreational and then as a profession.” Another participant said this about how substance 
abuse controlled her life: 
I was going through so much and never told anyone how I felt, just numbed it all 
away with drugs. I was high 24/7. I used to stay up for days, days. It was a terrible 
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way to live. My whole life was about heroin and cocaine and where I could get it 
and who had the best...I thought I had it going on. I went to jail many times. 
One man described how his substance abuse escalated from drinking alcohol in 
high school with his friends to snorting cocaine as a young adult. A decision to inject 
cocaine one time at a party changed this participant’s life forever: 
[It started] in high school. I think all guys start drinking in high school and it’s 
kind of one of those things. At first it was a fun thing, and I thought it was 
something I could control. You go out to a club on the weekend, and get drunk. 
First it was one night, then two to three times a weekend, then it was every day… 
So it wasn't a party anymore, it became an issue. Margaritas and lines of cocaine. 
It started out as a recreational line, then doing two or three at work. I was at 
someone’s house, we had all been doing cocaine, and someone mentioned a 
needle. We didn’t know about the needle-sharing thing. When you are under the 
weather like that, your judgment is way off. Somebody had suggested trying this. 
They were doing the thing with the needle and cotton ball and injecting it. At first 
I said no, I don’t do needles, I don’t like that kind of stuff, I never have… As far 
as recreational, I never had access to it. That is the one and only time it ever 
happened to me. That is why I am here today. 
Being around others who injected drugs was another reason for substance abuse 
escalation. One participant said: 
I used everyday for a while and I use to be a sniffer although all my friends used 
to shoot up. One time I tried it for a month. I don’t consider myself an IV user. I 
guess since I tried it, I am. 
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Another participant said “I started doing heroin at the age of 32. I got HIV from 
sharing a cocaine needle.” She went on to say “I should have just kept snorting it.” She 
also said she was getting “high” with the person she was buying the heroin and cocaine 
from and she knew this person was infected with HIV. She said “I kept sharing [the 
needles] anyway.” Anther person said “drinking alcohol leads to smoking pot” then on to 
“smoking dope.” 
One participant appeared to be impaired on drugs during the interview. He 
admitted to injecting heroin on top of his daily methadone dose. He said he just wants to 
get high because “I have no life, no career, no family, and no friends.” He said he used to 
inject heroin with friends when he was younger, but he said “now I just do it by myself.” 
He knows the use of heroin is illegal and it is harming his health, however he said there is 
“not much else to do.” A second person admitted to injecting heroin in addition to his 
daily methadone dose. However he said “I am high on methadone and I can’t really feel 
[the heroin]. The high lasts about five minutes, so I don’t even bother.” 
The participants who were children when they started abusing drugs and alcohol 
also described an escalation pattern to their substance abuse. One participant said: 
I started drinking real early, probably about eight or nine. I’d steal beers out of the 
refrigerator, and the parents would get a little loaded and then they wouldn’t miss 
them. When I was about 12 years old, I started smoking a lot of pot and doing 
LSD and that went on for a number of years…I was about 33 when I started 
shooting heroin and drinking [in combination]. 
Nine (29%) participants described how if they drank alcohol it stimulated the 
desire to abuse other drugs such as marijuana, heroin, or cocaine. One participant said “it 
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started with the alcohol and then I went out there and got high. I know where to go [to 
purchase crack and heroin].” Others said once they start drinking they consumed harder 
drugs:  
• “When I drink I want to do other drugs, marijuana or dope” 
• “Alcohol and marijuana equals heroin,” 
• “When I drink beer or Bacardi I want the crack,” 
• “I start drinking I start shooting heroin, not a pretty combination.” 
Polysubstance Abuse 
Twenty-nine (94%) participants self-identified substance abuse problems with 
two or more substances. The most problematic substance was heroin, followed by 
cocaine and alcohol respectively. Participants described their abuse of multiple 
substances:  
• “I was shooting heroin and drinking,” 
• “Drinking heavily and smoking pot, and then it was drinking and heroin,” 
• “I used lots of drugs and alcohol. I was using cocaine for about 20  years, 
then it was the mixture of cocaine and heroin, the speedball in addition to 
alcohol,” 
•  “It was acid, hallucinogenics, heroin, a mixture of anything I could get 
my hands on.” 
Normalcy: A Family of Addicts 
Six (19%) participants said that alcohol and drug abuse were a normal part of 
growing up. They spoke about how parents or family members were abusing drugs and 
alcohol and it was not unusual to be exposed at an early age. For example, one man said 
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he abused drugs and alcohol because it was accepted in the community where he was 
raised. He said “I thought this was how everyone lived.” He also stated: “I thought 
everyone did something—alcohol, drugs, or smoking—to take the edge off.” In addition, 
substance abuse was multigenerational for some participants. They said their parent(s) 
and they themselves were substance abusers. In addition, two had children who were 
substance abusers. One participant had a child in jail on drug-related charges. One man 
described how two of his close family members were dying from liver failure due to their 
HCV infection and “they had been serious alcoholics all their lives.” 
The Enemy Within 
Some of the participants spoke about their substance abuse as something within 
themselves that they could not control. For example, one woman said this about her drug 
addiction: “My disease is telling me I can get high and don’t have to worry.” Another 
said: “Drugs were my whole life; I would do anything or steal anything just to get drugs.” 
Anther person said he knew he was an alcoholic and he needed to “control” something 
within himself. He said, “I am a binge drinker…I lied to my physician about my 
drinking.” A fourth person said: 
I don’t know what’s wrong with me. What is really going on? I guess the disease 
is telling me to get up and go. That is all I have been doing, just running from my 
problems. I have been doing drugs all my life. 
Transmission and Disclosure 
Twenty (65%) of the participants said they knew they contracted the HIV/HCV 
co-infection from injecting drugs. Four (13%) thought they could have been infected with 
HIV/HCV co-infection through unprotected sexual contact. One participant said: “I could 
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have been infected with both from my husband since I was injecting drugs and having 
unprotected sex with him.” Another woman said: “My boyfriend told me he was HIV 
positive right after we had unprotected sex.” She said she thinks she was infected with 
both the HIV and the HCV infections at the same time. She also said she was injecting 
heroin. Another woman said “my boyfriend deliberately infected me” with both HIV and 
HCV infections; however she did not elaborate further. One man said he was relieved to 
know that he probably contracted both infections because of his injection drug abuse 
rather than sex. He said “I would be frustrated in knowing that sex may have been the 
cause.”  Another participant described how he would “go out drinking and drugging in 
the bars” and then “I would pick anyone up, I would take them home [for sex]. I was 
doing both, sharing needles and having [unprotected] sex.” 
Despite knowing their HIV infection and HCV infection status, many (n = 29) 
continued to abuse drugs and alcohol after their diagnosis. One participant said he was 
“shooting dope like mad” when he was diagnosed with HIV 19 years ago and had a 
physician tell him “You need to stop [doing drugs] or you are going to die.” He admitted 
he was still injecting drugs at the time of the interview. 
Five (16%) of the participants disclosed they were active substance abusers at the 
time of the interview. Of these participants, three were women and two were men. All 
five were single and unemployed. Four were abusing alcohol. Two were injecting heroin 
and one was smoking it. The two participants injecting heroin said they were not sharing 
needles; they made these comments about their injection practices: “I haven’t shared 
needles in years,” and “I just do it by myself.” One participant was drinking alcohol and 
smoking crack cocaine. Two of the participants actively using a combination of drugs and 
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alcohol drugs were in a residential treatment facility; the other three were living on their 
own. Both participants in the residential treatment had recently entered the program. One 
participant was moving into the residential treatment facility the day of the interview and 
the second had been admitted for two months. All five of the participants were on HIV 
medications and two had AIDS. Only one of the five participants with active substance 
abuse problems had undergone a liver biopsy and none had started HCV treatment.  
All five of the participants with active substance abuse problems had been 
diagnosed with depression. However, only one of the five (20%) was taking medications 
to treat the depression, compared to 20 (65%) who were not active substance abusers. All 
five current substance abusers described their current mood and emotions as “anger,” 
“frustration,” “ bitterness,” “loneliness,” and “depression.” They also said:  
• “I know I need help, but I am always running from my problems,”  
• “I am frustrated, angry, and bitter,” 
• “I blame my family for my problems,” 
• “I feel like I am always getting bad news,” 
•  “I don’t trust anyone.” 
One participant said “I am always starting over” [with rehabilitation] and “I am still 
standing in the same place as I have always been in.” They described how they responded 
to negative emotions or events by turning to drugs and alcohol. All five of the 
participants seemed to be tired of their substance abuse problems; however they did not 
have the necessary skills to overcome them. Two participants spoke about their belief in 
“God” or “a Higher Power.” Both were asking God or their Higher Power for help and 
strength to get through their personal problems and substance abuse issues. 
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Revolving Door: Going Back Out 
Revolving Door: Going Back Out was the second major theme to emerge from 
the data analysis. One participant described relapse as “going back out” into the drug and 
alcohol scene. Twenty (65%) of the participants spoke about how they would go through 
substance abuse recovery, either on their own or through a treatment facility, and then 
relapse back to substance abuse. Some participants shared the number of times they have 
been through substance abuse rehabilitation. For example: 
•  “I have been here [inpatient treatment facility] a couple of times before,” 
•  “It took me three detoxes to get all the heroin out of my system,” 
•  “I have been in and out of recovery many times. Three months here, a 
year and half there,” 
• “I have been in this program three times. I gave up my freedom to come 
back here.” 
One participant currently in a residential treatment facility said “I don’t 
understand. I am the one always going out and relapsing.” Several said they felt 
“ashamed” of their relapse into substance abuse. 
It was also interesting to note that the definition of relapse was different among 
the participants. One participant said she would “stay clean and sober all week” and then 
she would relapse on the weekends. Another woman said she was “always going out and 
relapsing” rather than realizing she was in a pattern of continual drug abuse. Another 
woman said: “I am looking for an easy way out into addiction.” This participant admitted 
she used any excuse to abuse injection drugs.   
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The participants also described the triggers that caused them to return to substance 
abuse, such as stressful life events, emotions, alcohol, or their destructive relationships 
with others. 
Stressful Life Events as a Trigger 
Seven (23%) participants described specific events in their lives that triggered 
substance abuse relapse. For example, one participant said the death of her young child 
caused her “to lose it” and she started injecting heroin again because she did not care 
about anything anymore. Other events that triggered relapse in the participants included 
the death of a brother, a husband, and the suicide of a brother. Another participant 
described how she “wound up going back out” after receiving the HCV diagnosis. 
Another woman said she would relapse once she was off probation because she was no 
longer required to provide urine samples for her probation monitoring. One participant 
was in a car accident and started using heroin again to control the pain she suffered from 
her injuries. She said this about the use of heroin to control the pain: “I had other choices, 
it’s just I wanted to use [heroin]. I loved the way it made me feel.” 
Emotions as a Trigger 
Nine (29%) participants said their emotions such anger, low self-esteem, 
boredom, pain, or fear were triggers for substance abuse relapse. Seven (78%) of the nine 
individuals with an emotional trigger were women. Two men said they used drugs or 
alcohol to manage their anger or anxiety. 
Anger was a common trigger for relapsing. One woman described how she felt 
“everyone was always picking on me” and it made her angry and frustrated causing her to 
use drugs and to drink alcohol. For another woman, both anger and drinking alcohol were 
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triggers for her to inject heroin. She said: “When I become angry or frustrated I want to 
drink and then I want to go out and find something to smoke.” One woman said her 
mother was her trigger. She said she will speak to her mother on the phone, however she 
knows that if she visits her she knows they will wind up fighting, which will trigger the 
desire to use drugs. She said “she aggravates me so therefore I go out and use.” 
Three (10%) people said their low self-esteem was a trigger for substance abuse 
relapse. One participant discussed how she has a very low self-esteem and does not have 
any friends. She said “I am very focused on my children and grandchildren, but I feel I 
need to get a life of my own. I am always trying to take care of everyone else except 
myself.”  However, she did say this about her substance abuse recovery: “All the people I 
used to associate with are in the past and I am not going back.” A second participant 
spoke about how his compulsive behavior led to the risks he took while he was abusing 
drugs and alcohol. He said: “Through my compulsive behavior in the midst of my drug 
use, I took all kinds of chances. I wasn’t even concerned about myself or my life. I did 
not respect others.” The third person described depression as her trigger for heroin use. 
She said “I was so depressed. If I sit too long in my own head I’m going to resort to old 
behavior.” In response to this statement she reflected: “I now ask for help [through her 
sponsor at the rehabilitation center].” 
One woman said pain was her trigger: “Pain is a big trigger for me. Physical pain 
I can’t deal with. That is what makes me relapse 80% of the time.” She said she received 
a prescription for Oxycodone to help manage her pain, but she relapsed after taking them, 
so she said: “I just deal with the pain, I guess.” 
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Alcohol as a Trigger 
Thirteen (42%) participants described alcohol as a trigger for substance abuse and 
11 (85%) of the 13 participants said their substance abuse escalated once they started 
drinking. For example: Another participant said: “I thought I was missing something [by 
not drinking] so I started drinking again. I like the taste of beer. I know I can’t handle it.” 
One woman said she knows she is going to relapse when she starts drinking and smoking 
marijuana. This caused her to move onto harder substances, especially heroin. Another 
person said when he started drinking alcohol “it just leads to more heavy drinking and 
smoking pot and then onto injecting heroin.” 
Destructive Relationships as a Trigger 
Eight (26%) participants, seven women and one man, felt that their substance 
abuse was connected with their romantic relationships. The women said they became 
involved in drugs because they were “young,” “uneducated,” or “controlled” by the men 
with whom they had relationships. Furthermore many described dysfunctional 
relationships with their spouses or their partners as major contributors to their substance 
abuse problems. One woman said: “Usually it [substance abuse] had to do with my 
relationships. I was meeting the wrong kind of guys. Going nowhere, same kind of 
people. I couldn’t get out of that cycle.” A second women said she was in an “unhealthy 
relationship” with a man for nine years that included alcohol and drug use. She said she 
also was “distributing drugs” and “was out on the streets selling myself to pay off his 
drug debts.” Another woman said she “felt like I was never good enough for them [the 
men]. I was always in an abusive relationship.” Another woman called her relationship 
with her husband an “insane marriage, all dysfunctional. It was one big mess.” She also 
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said, “He had magical powers over me and he was like a god.” She said her mission in 
life was to take care of her husband by providing the drugs and alcohol for the 
relationship. She said she “would steal or do anything in order to get the drugs and 
alcohol. I got very selfish, the criminal behavior started coming out in me. I did things I 
would never do today.” Another woman admitted she was currently drinking alcohol in 
place of doing heroin. She said when her boyfriend left her four years ago “I started 
drinking when he left me” and “he really did screw up my life.” She said she drinks 
because she is bored, lonely, and depressed. All of the women confided they were no 
longer in these relationships. 
The one man that said his relationship with a woman was part of his substance 
abuse problem said this woman enabled him by providing him with anything he needed, 
especially money. He said, “Once I broke off the relationship with her, I was able to start 
working on my sobriety.” None of the other men elaborated on their past relationships 
with significant others or how these relationships may have impacted their substance 
abuse habits.  
One man did mention he was now married to a woman who was not infected with 
either HIV or HCV and he was surprised that she was willing to be with him since he had 
both diseases. Another man said, “I am now married and I have a child since I gave up 
drinking and injecting drugs.” 
Reconstructing Life 
Reconstructed Life was the third major theme to emerge from the data analysis. 
Sub-themes that came out were defining moments, maintaining sobriety, and setting 
priorities. Twenty-six (84%) of the participants were in various stages of recovery 
75 
ranging from a few months to 17 years. They were learning to accept themselves without 
substance abuse to relieve the emotions that they typically concealed or treated by using. 
This learning process was especially apparent in those who were new to recovery or in 
those who had relapsed and were returning to a life of sobriety. The participants spoke 
about defining moments that helped move them toward sobriety in order to reconstruct 
their lives. They also described how they were maintaining sobriety and setting priorities, 
even if it meant doing so one day at a time. 
Defining Moments 
Eight (26%) participants described experiencing a defining moment that helped to 
propel the participants towards sobriety. One participant described in detail a defining 
moment that he considered a turning point in his life: 
Through my compulsive behavior, while being in the midst of my drug use, I took 
all kinds of chances. I wasn’t even concerned about my life…[I] became more 
self-destructive. I actually had a spiritual experience that really turned my life 
around. It was a cold, misty morning in Boston, I hopped on a bus and I had this 
flash. It must have lasted a tenth of a second. I was going through the tunnel and I 
had somebody’s hand. But I had a sense of comfort, peace, security. 
 He went on to describe how he faced his addictions and a dysfunctional relationship with 
a woman who was enabling him to use drugs by providing him money and housing. He 
went through rehabilitation and “got his act together.” 
Two participants said that receiving the diagnosis of HIV infection saved their 
lives. One man said he stopped injecting heroin and drinking alcohol after his diagnosis. 
He said: “Once I stopped using heroin, everything was a piece of cake. And that’s how I 
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made myself believe that really it [HIV] saved my life. I probably be dead by now if I 
didn’t.” Another participant said that being diagnosed with both HIV and HCV four years 
ago saved his life too because he made major life changes after his diagnosis, including 
becoming clean and sober. 
One woman said she stopped using drugs when her child tried to commit suicide, 
scaring her into sobriety. Another participant said by nearly becoming homeless he made 
a commitment to himself about his sobriety that changed his life: 
I was close to being homeless when the love of my life tossed me out. Nobody 
wanted me. I moved into a sobriety house. I did not know if I could do it [get 
clean and sober]. I don’t want to let people down [by relapsing]. A lot of good 
things have happened in my life in the past five years that I wouldn’t want to give 
up for anything. 
Finally, realizing that help was available and asking for it were defining moments 
for some participants. One person described how she asked for help before she relapsed 
again. She said: “I have never asked for help or support so this was a milestone for me.” 
She said she finally admitted she was an addict and said she needed help. She said she 
wanted her children to be proud of her. She also said: “Nobody can say she went out and 
got high in the end.” Another participant realized she was not ready for sobriety and her 
attitude was holding her back in her recovery: “I did not want it. Now I want it! I don’t 
want to relapse. I love myself, I don’t want to get sick with full blown AIDS!” 
Maintaining Sobriety 
Twenty-six (84%) of the participants had experienced sobriety—ranging from a 
few months to 17 years—and staying clean and sober was a priority for many of them. 
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They managed their substance abuse recovery “day-by-day,” by “keeping busy,” and by 
“dealing with emotions and stress.” Others said they are “giving the day to God” to 
manage their recovery. Support groups have been helpful for a number of the 
participants. Still others have gotten out of destructive relationships that enabled their 
substance abuse. The importance of maintaining sobriety was especially apparent for six 
individuals in a residential treatment facility. Major goals for these residents included 
staying substance abuse free, being united with family and minor children, and obtaining 
and maintaining their own home. The residents of the facility as a whole felt they wasted 
much of their lives abusing drugs and alcohol. One participant said: “I realized I don’t 
have to drink or do drugs to have fun,” and “This is the first time my mother has seen me 
sober in 13 years.” Another participant said she was taking advantage of everything she 
lost when she was “using and abusing.” Being tired of the consequences of substance 
abuse was cited by one participant as a reason for her sobriety. She said, “I’ve always 
been using drugs. I never thought I’d be able to stay clean. Just last year it got to the point 
where I was sick of the consequences.” One of the women said she was sober because “I 
don’t want my grandchildren to remember their grandmother as some loser, some drug 
addict.” 
Nine (29%) participants felt their belief in God or a Higher Power was an 
important part of their sobriety and recovery. These statements they gave were similar to 
the terminology used in 12-Step recovery programs. For example: 
• “I give God the day and my goal. I try to if I can [stay clean],” 
• “I give my day to God. Yesterday is gone. I am working [on my sobriety] 
one day at a time,” 
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• “God is a beautiful God and he has given me strength every day to restore 
my sanity.” 
Others said they believed God had a plan for them. For example: “I believe God is not 
going to let me suffer if I [do] the full work. Stay clean” and “God had something 
important for me to do and I am not done living.” Another felt God was in charge of his 
life and he said “If it wasn’t for God, I wouldn’t be here.” 
In order to maintain their sobriety, three (10%) participants said they were 
involved in Alcoholics Anonymous or Narcotics Anonymous support groups. Eleven 
(35%) others said they were involved in rehabilitation or support groups, but did not 
identify the programs. The participants in recovery spoke about how they maintained 
their sobriety by “surrounding myself with people who don’t consume alcohol or drugs,” 
“going to support groups,” or “talking to others” (i.e., friends, family, psychiatrists, 
healthcare providers) about their problems. One man said he maintains his home as a 
“drug and alcohol free zone” in order to stay sober. He said anyone who comes to his 
home knows they are not allowed to be drunk or high on drugs. 
Four (13%) participants said they did not belong to a substance abuse recovery 
support group because they felt they were not helpful. One person said “they [support 
groups] are not for me.” Another said the meeting irritated her so she would not go back. 
Eight (26%) of the participants (both women and men) mentioned how getting out 
of destructive and abusive relationships with their partners helped them to obtain and 
maintain sobriety. In addition, they also worked to stay away from family members or 
others who put their sobriety in jeopardy. One woman said she realized anytime she went 
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to Boston to visit certain people, she knew she was in danger of using drugs so she stayed 
away from them. Another participant had this to say about her sobriety: 
There is nobody, including my children that I would put my recovery in jeopardy 
for. Don’t get me wrong; I’d die for my kids. I love them all. But if they are going 
to jeopardize my sobriety, I can’t be around them. I won’t be around them. 
The participants also said keeping busy helped in managing their sobriety. Two 
men went fishing frequently, one hiked and skied, and another played golf as often as he 
could. Women said they walked, read books, volunteered, and practiced yoga to manage 
their sobriety. Sobriety was fragile for some. For example, one woman said “I keep busy 
so I don’t sit in my head for too long.” She added, “If I have too much idle time, I will 
resort to my old ways.” 
Four (13%) participants spoke about how they managed stressful or emotional 
situations to maintain their sobriety. Instead of using heroin to cope with stressful life 
events one woman said, “I am learning how to deal with stressful situations.” Similarly, 
another woman discussed her ability to assess stressful situations and consider the 
consequences if she used drugs. She said “I am not wiling to give up what I have worked 
so hard for [by using drugs].” Another said: “I have learned how to be independent. I 
have leaned that I don’t have to do drugs to deal with my feelings.” Likewise, one man 
said: “I don’t have to sedate myself to deal with my problems now.” 
Aim 1 Summary 
Participants in this study described their substance abuse experiences in detail. All 
of the participants had past or present substance abuse issues. Many (n = 20) knew they 
had HIV/HCV co-infection because of their injection drug abuse. Three major themes 
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with sub-themes emerged during the data analysis, including: (1) Substance Abuse 
Evolution (with sub-themes: substance abuse initiation, escalation, polysubstance abuse, 
normalcy: a family of addicts, the enemy within, and transmission and disclosure), (2) 
Revolving Door: Going Back Out (with sub-themes: specific events as a trigger, emotions 
as a trigger, alcohol as a trigger, and destructive relationships as a trigger), and (3) 
Reconstructing Life (with sub-themes: defining moments in substance abuse addiction 
and maintaining sobriety). 
Aim 2: Impact of Substance Abuse on HCV Treatment Decision-Making 
All of the participants in the study knew they were infected with both HIV and 
HCV infection. Some of the participants received the HCV infection diagnosis at the 
same time as the HIV infection diagnosis. Others did not find out about their HCV 
infection until many years after their HIV infection diagnosis. Twenty (65%) of the 
participants said they knew they contracted both HIV and HCV infections from injection 
drug use, though when some received the diagnosis they were unsure of how they 
contracted the disease until it was explained to them.  
Upon receiving the diagnosis of HCV infection, the participants said they felt 
scared (n = 4), embarrassed (n = 2), shocked (n = 2), confused (n = 1), surprised (n = 2), 
devastated (n = 2), or angry (n = 1). Others never gave the HCV diagnosis much thought 
(n = 12) or blocked the diagnosis out of their minds (n = 2). One participant said this 
about the HCV infection diagnosis: “it’s just another day and one more disease to add to 
the list.” Nearly half of the participants (n = 13) disclosed they were injecting drugs at the 
time of their HCV infection diagnosis. One participant, who was embarrassed and was 
worried about telling his friends he was infected with both HIV and HCV said “when I 
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was out there using, it was harder telling them [my friends] not to use my syringes.” One 
patient relapsed and started injecting heroin again when she received the HCV infection 
diagnosis. She said: “So, I wound up going back out. I had two years clean and I wound 
up going to use and said if I’m going, I’m going hard. But then I realized I was still OK.” 
One participant was selling her blood through transfusion donations to obtain funds to 
purchase heroin. She said: “I was angry and could not believe the [HCV infection] 
diagnosis. I asked for the test [HCV] to be repeated.” 
Themes and sub-themes emerged regarding HCV treatment decision-making from 
the data analysis: (1) HCV Infection Treatment Issues (HCV treatment: not a priority, 
fear, misinformation); (2) Get Clean and Try It (desires to use stimulated during HCV 
treatment). 
HCV Infection Treatment Issues 
HCV Treatment Issues was the first major theme concerning the impact of 
substance abuse on patient HCV treatment decision-making. There were two distinct 
groups with respect to decision-making information related to HCV treatment. The first 
group consisted of ten participants (32%) who were currently receiving or had completed 
HCV treatment at the time of the interview. The second group consisted of 21 (68%) 
participants who had not received HCV treatment. Figure 2 below outlines HCV 
treatment outcomes in this sample. 
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Figure 2. Current or Previous HCV Treatment or No HCV Treatment Flowchart 
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Of those participants who had not received HCV treatment, there were two sub-groups. 
The first sub-group (n = 6) consisted of five men and one woman who were pursuing 
HCV treatment. These participants were moving towards treatment by starting the 
pretreatment evaluation, but they had not started treatment at the time of the interview. 
They also were making arrangements for dependent children, arranging time off from 
work, and asking for assistance from family and friends.  
The second sub-group (n = 15) consisted of participants who had not undergone 
HCV treatment for a variety of reasons. Six women were focused on substance abuse 
recovery and sobriety. Four women were scheduled to start treatment, but backed out for 
unknown reasons. Two men were active substance abusers and thus ineligible for 
treatment. One man said he would consider treatment if he had more information. And 
finally, two participants, one man and one woman, gave no reason for not pursuing 
treatment. 
HCV Treatment: Not a Priority 
For some of the participants, HCV treatment was not a priority. For example, 
some of the participants said they had not thought that far ahead, but would consider 
HCV treatment if they needed it. One person was awaiting results from a recent biopsy 
and feared she had cancer and HCV treatment was not a priority for her at this time. One 
group (n = 6) was focused on substance abuse recovery and staying clean and sober and 
treatment of their HIV infection. For this group, treatment of their HCV infection was not 
a priority at this time. 
Some were afraid that they were going to die from their HCV infection before 
they died from complications of their HIV infection while others did not give their HCV 
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infection or treatment much thought. One participant was scheduled for a liver biopsy but 
felt she was healthy and did not need HCV treatment. She said, “I am unsure if I will 
keep that appointment.” Others were actively abusing drugs and HCV treatment was not 
a priority. For example, one participant said, “I was so high I never noticed.”  
Fear: Substance Abuse Issues and HCV Treatment 
Some participants were fearful that the HCV treatment would cause them to 
relapse back into substance abuse for one of two reasons: (1) if they were in possession of 
the syringes used for the interferon injections, their desire to use injection drugs would be 
stimulated, or (2) the desire to use drugs would be stimulated while they were drawing up 
the interferon for the injection. One woman said, “For my own sanity and safety I prefer 
to come in and have the injections. I prefer to have the [interferon] injections at the clinic 
for my own sobriety.” 
In addition, two women were fearful their toddlers would somehow manage to 
pick up used interferon needles and get stuck, thus becoming co-infected. One of these 
women said: “I have a baby, and if for some reason I got sick and I dropped one [of the 
needles] and he picked it up…he’s not HIV or HCV positive. He is a miracle.” 
To keep from having needles accessible, some participants decided to let their 
healthcare provider give the weekly interferon injection. They felt this was a way to 
control their fear and the possibility that the needles could trigger a relapse. They knew if 
they were in possession of the needles used for the interferon injections, the desire to use 
injection drugs would be stimulated. One man took the first few interferon injections at 
the healthcare facility and then decided he was able to give himself the injections after he 
felt strong enough to handle having syringes in his home. One man who was fearful that 
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the desire to use drugs would be stimulated while he was drawing up the interferon for 
his injection devised a technique to get himself through the treatments. He explained, “I 
forced myself to think that I was not putting drugs into the needle in order to get through 
the treatment. That’s how I did it.” And this technique worked for him—he was able to 
stay clean and sober throughout his HCV treatment. One participant was unable to give 
herself the interferon injection because she developed an extreme fear of needles. She 
said “touching the needle makes me physically sick since I stopped using heroin ten 
months ago.” She arranged for the nurse at the clinic to inject the interferon. 
Misinformation:  Substance Abuse Issues and HCV Treatment 
Misinformation about HCV treatment and the impact of substance abuse among 
the participants was varied. For example, one participant misunderstood how consuming 
alcohol could impact her hepatic function and health. She was under the impression that 
she could resume drinking after she completed HCV treatment. She said “I can stop 
drinking alcohol [while on HCV treatment] and I will know in about three months if the 
treatment is going to work.” She said: “I can go back to drinking [alcohol]” after 
completing the HCV treatment. She added: “I drink alcohol in place of injecting heroin.” 
This participant’s physician and family were encouraging her to go into rehabilitation for 
her alcoholism before she attempted HCV treatment.
Two participants were unclear of the risks associated with HCV infection on their 
long-term health outcomes. They thought if they stayed clean and sober they would 
remain healthy and their HCV infection would remain stable. One participant in 
particular said, “I don’t need to be on interferon, my liver is fine. As long as I don’t pick 
up and drink and drug, I will be fine.” Anther participant said he was not addressing the 
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need to treat his HCV infection because “long as I keep busy and I eat healthy and I don’t 
drink and drug and I seek out advice and I take my medications accordingly, then 
everything will be all right.” 
Desires to Use Were Stimulated During HCV Treatment 
While going through HCV treatment, some participants experienced sensations 
similar to their substance abuse. The participants described feeling these sensations, 
however none admitted to acting upon these urges. They were able to use techniques or 
strategies to maintain sobriety during HCV treatment. Three participants said that taking 
interferon made them feel like they were “detoxing” or “kicking it” from heroin. One 
man said he had “the psychological sense of injecting” while he was undergoing HCV 
treatment. He said his lips were “smacking” and “salivating” similar to when he was 
injecting cocaine. He went on to say, “I had to sit back and process, think about and 
figure out exactly what was happening.” Another one of these participants said that HCV 
treatment “makes you want to commit suicide. If it is not the suicide, it’s going to the 
drugs and you going to hit the streets.” The participant suggested that anyone undergoing 
HCV treatment with a history of substance abuse “get counseling and fight the urges” the 
[HCV] treatment induces. 
Get Clean and Try It 
The participants who had already undergone HCV treatment had advice for others 
who were considering treatment for their HCV infection: be clean and sober and get the 
treatment. One man commented: “If there is any chance, even 10% of cure, do it. Try it.” 
In addition, the participants who had undergone HCV treatment added, “Get counseling 
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and join support groups,” and “Get all the help you can with your substance abuse 
recovery.” One participant had this to say about sobriety and HCV treatment: 
Probably, out of everything I say, the biggest thing I have done to help myself 
with this treatment is not using drugs and alcohol, because I’m an alcoholic and 
drug addict. I would have waited at least a couple of years before [HCV 
treatment], you need some kind of support system. 
Another participant felt it would be important for those considering HCV 
treatment be sober for at least two months. She also felt it would be misuse of medical 
resources if someone was still using drugs and was trying to make a decision to start 
HCV treatment. She had this to say about importance of sobriety before starting HCV 
treatment: 
I think it’s important to be clean and sober. At least a few months, because if you 
are using, you are defeating the whole purpose of doing the medication. If you are 
really sincere about getting clean and taking care of yourself, I do believe you 
should be clean though. Medication is very expensive, so if you’re using drugs or 
alcohol while you are doing the treatment, it’s kind of a waste of money and 
energy and time. 
Another participant had the same thoughts: “A person considering HCV treatment should 
be stable in their recovery before beginning the treatment.” He added, “When someone is 
considering HCV treatment they should be having regular counseling sessions or be 
involved in a support group since the [HCV] treatment can stimulate the desire to abuse 
drugs and alcohol.” 
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Another participant recommend that those going through HCV treatment should 
smoke marijuana to ease the side effects of interferon. He said: “The treatment 
[interferon] causes flu like symptoms which is so similar to [narcotic] withdrawals that it 
makes you want it [narcotics] more than the treatment.” He said he smoked marijuana 
throughout his HCV treatment to eliminate the nausea and that he preferred to smoke 
marijuana rather than relapse back to using heroin. 
Aim 2 Summary 
Substance abuse experiences related to HCV treatment decision-making were 
threaded throughout the interviews. Preliminary descriptive data were present that 
suggested possible links between substance abuse and HCV treatment decision-making; 
however information redundancy was not reached for this second aim. Therefore, the data 
presented below represents an initial description that will require greater exploration in 
future studies. 
Participants described how they felt when they were diagnosed with HCV 
infection and their fear of HCV treatment. There were some misconceptions about 
substance abuse and HCV treatment. In addition, participants who were currently 
undergoing or had completed HCV treatment, had advice for those contemplating 
treatment. Participants described how the desire to abuse drugs or alcohol occurred and 
how they managed these feelings during HCV treatment. Detail about these linkages will 
be detailed according to patient and contextual factors below. 
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Secondary Aim: Exploration of Substance Abuse Experiences within Interactive 
Decision-Making Framework 
Rich descriptions of substance abuse experiences were threaded throughout the 
interviews. These descriptions were evaluated to ascertain whether they fit best with 
patient or contextual factors within the Interactive Decision-Making Framework (Pierce 
& Hicks, 2001). Based on the available data, it is unclear whether substance abuse 
experiences fit with patient or contextual factors. The substance abuse experiences in this 
sample included both patient and contextual factors. 
Patient Factors 
In this study, substance abuse experiences could fit within patient factors since 
many of the participants had a history of long-term substance abuse problems. 
Participants also said they had choices when it came to substance abuse relapse. For 
example, one participant said she chose heroin to control her pain after an accident: “I 
had other choices, it’s just I wanted to use [heroin]. I loved the way it made me feel.” 
Still others chose not to accept prescriptions for narcotics after a medical procedure such 
as a liver biopsy. One man said “It [the liver biopsy] hurt afterwards. I refused it [pain 
medication]. I just didn’t want to start taking anything.” This comment indicated he was 
unwilling to put himself at risk for a relapse. 
In addition, according to the framework, decision values are associated with the 
patient’s perception of experiences and momentary states of pleasure and pain. Data from 
this study linked decision-making to these momentary states. For example, participants 
explained that their substance abuse made them “feel good.” Another participant said “I 
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just want to get high.” Participants described how they used drugs to “calm,” “numb,” or 
“control anxiety.” 
Patient Factor: Decision Styles 
There was a range of decision-making styles across the sample. Some patients 
expressed their abilities to take charge of their HCV infection by doing whatever it takes 
to treat their HCV infection, including staying free from drugs and alcohol. They felt the 
need to make the decision to have HCV treatment to stay alive, be around for their 
children. None of the participants who were moving toward HCV treatment were actively 
abusing drugs or alcohol nor were they in the residential treatment facility. 
One participant said he had made the decision to move forward with HCV 
treatment and felt ready. He said he has been clean and sober for nine months. However, 
he said his healthcare provider wanted him to have more time with his sobriety. In 
contrast, another participant who was currently undergoing HCV treatment said “I did 
heroin 10 months ago and I decided to become sober.” She was currently undergoing 
HCV treatment and having the nurse at the clinic give her the interferon injections 
because she was fearful of having the needles in the house. 
Conversely, some participants said they had trouble making commitments and 
they knew the treatment would require a long-term obligation on their part. Some 
participants (n = 6) were focused on their substance abuse recovery and HCV treatment 
was not a priority for them. One participant said this: “It is serious treatment. It is nothing 
to play around with. It is very expensive. You really have to want it because it is a 
commitment.” She went on to say: “If you are using drugs you are wasting your time and 
the doctor’s time and it is a waste of medication.” She felt that making a serious 
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commitment to HCV treatment meant that someone was serious in their commitment to 
their sobriety. 
Patient Factor: Preferences for Participation 
Some participants were actively involved in the HCV treatment decision-making 
process. Some participants made the decision to wait for the right time to begin HCV 
treatment. One participant had this to say about the decision to start HCV treatment: “The 
biggest concern that I had was I waited until the golf season was done, then we waited for 
the holidays to go because we thought all these things could happen…I was like, what 
was I waiting for?” 
Another participant decided it was a good time to treat her HCV infection based 
on the stability of her HIV infection. A second woman also said she decided to go 
forward with HCV treatment based on the stability of her HIV infection in addition to a 
feeling she had. She said: “My HIV is stable, the decision just feels right, and I want to 
live!” 
Four (13%) participants preferred to take more passive role in the decision-
making process. One participant said, “I take all the medications that they [doctors] want 
me to take,” and another said “I will leave the decision [for HCV treatment] up to my 
doctor.” Two others said they would leave the final decision for HCV treatment up to 
their healthcare providers. They said they trusted their healthcare providers to make the 
right decisions for them. 
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Contextual Factors 
Substance abuse decisions may also fit within the contextual factors of the 
framework because substance abuse occurred within the context of the individual’s 
environment demands. 
Contextual Factors: Patient-Provider Interaction 
Across the sample, the participants said their healthcare providers gave them 
“advice,” “education,” and support.” They also felt their healthcare providers were candid 
and realistic about their health care issues. Participants were told by their healthcare 
providers that their substance abuse could worsen their HIV infection or HCV infection. 
For example, one participant said: “They said it was because of my heavy drinking. They 
[healthcare providers] said you better make up your mind and quit drinking.” Some 
participants who have not made the decision to undergo HCV treatment said they needed 
more education regarding substance abuse issues. Several participants were fearful that 
the desire to abuse drugs or alcohol would be stimulated during HCV treatment. 
Across the sample, the participants said they had positive relationships with their 
healthcare providers and they made statements such as, “They work with you as a team,” 
and “We try to work together—which is a good thing.” Participants said they had trust 
and faith in their healthcare providers and the decisions they made together. One 
participant said “They [healthcare providers] have always been there for me.” Two 
participants said that God gave their healthcare providers the necessary knowledge 
needed to do their jobs. One participant said she was inspired by her healthcare provider 
to take HCV treatment. She said, “She [my healthcare provider] is like the Mother I never 
had.” 
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Only one participant expressed a problem with his healthcare provider. He said 
his healthcare provider treated him like a drug abuser even though this participant assured 
the provider he was not. He said he stopped taking his HAART and HCV treatment due 
to “personality problems” and the way the provider treated him like a drug addict. He was 
willing to speak to the providers again about HIV and HCV treatment; however he 
wanted to be very clear he was not abusing drugs or alcohol. 
Secondary Aim Summary 
Based on this analysis, substance abuse experiences fall into both patient and 
contextual factors within the Interactive Decision-Making Framework (Pierce & Hicks, 
2001). While most of the participants expressed a collaborative relationship with their 
healthcare providers, there was a need for further education regarding substance abuse 
issues and HCV treatment. Being clean and sober was an important factor in the decision-
making process for the individuals who had undergone or were currently undergoing 
HCV treatment. 
Chapter Summary 
In summary, results of this study identified five major themes with sub-themes 
after analysis of the participants descriptive summaries. They were: (1) Substance Abuse 
Evolution (with sub-themes: substance abuse initiation, escalation, polysubstance abuse, 
normalcy: a family of addicts, the enemy within, and transmission and disclosure), (2) 
Revolving Door: Going Back Out (with sub-themes: specific events as a trigger, emotions 
as a trigger, alcohol as a trigger, and destructive relationships as a trigger), and (3) 
Reconstructing Life (with sub-themes: defining moments in substance abuse addiction 
and maintaining sobriety), (4) HCV Infection Treatment Issues (with sub-themes: HCV 
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treatment: not a priority, fear, and misinformation, desire to use stimulated during HCV 
treatment), and (5) Get Clean and Try It.  
Nearly half of the participants started abusing drugs and alcohol as children or 
adolescents. For some, substance abuse escalation evolved over time, for others it 
progressed rapidly. Polysubstance abuse was a major problem for most all of the 
participants of this study. In addition, they had been abusing drugs and alcohol for much 
of their lives and knew they had been infected with HIV/HCV co-infection from injection 
drug abuse. The participants described triggers and stressful life events that caused them 
to relapse. There was a wide variety of triggers for the participants in this study, in 
particular, the death of a loved one and emotions such as anger and low self-esteem, and 
relationships with others were all mentioned. The use of alcohol also was a trigger for 
many of the participants. Once some of the participants started drinking alcohol, they 
began using other drugs. Many of the participants had been in substance abuse 
rehabilitation at some point during their lives and the 12-Step program terminology was 
threaded through the interviews. They also spoke about how they were maintaining their 
sobriety with a variety of techniques such as taking it one day at a time, attending 
meetings, spending times with family and friends, and participating in hobbies or 
activities. 
Most were receiving HIV treatment, but a majority had not undergone HCV 
treatment for a variety of reasons. However, over half of those who had not undergone 
HCV treatment were active substance abusers or were in substance abuse treatment. For 
some, HCV treatment was not a priority for them at the time of the interview. Some of 
the participants were fearful the HCV treatment would stimulate the desire to use drugs 
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or alcohol. Some were unclear on how HCV infection could impact their long-term 
health. 
Being clean and sober was an important recommendation from those who were 
undergoing or had completed HCV treatment. These participants also wanted others to 
know that their substance abuse could be stimulated by HCV treatment and suggested 
that anyone going through treatment get all the help that one can to overcome the urge to 
relapse. Further work is needed to explore how substance abuse experiences impact the 
patient decision-making process. 
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Chapter V 
Discussion and Implications 
Introduction 
The purpose of this study was to describe the substance abuse experiences in 
adults with an HIV/HCV co-infection and to explore how these experiences may relate to 
HCV treatment decision-making. A secondary aim was to investigate where substance 
abuse experiences fit within the Interactive Decision-Making Framework (Pierce & 
Hicks, 2001). The following discussion reviews the major study findings according to 
substance abuse experiences, which includes substance abuse evolution; relapse, triggers, 
and recovery; the 12-Step language; and alcohol abuse in HCV infection. The limited 
data related to substance abuse experience and HCV treatment decision-making is 
summarized as is the lack of a clear fit of substance abuse within the decision-making 
framework. Finally, implications for the nursing field and recommendations for further 
research are outlined. 
Substance Abuse Experiences 
Substance Abuse Evolution 
For the participants of this study, substance abuse was an evolutionary process 
that proceeded from initiation to escalation, and included polysubstance abuse. Nearly 
half became substance abusers as children or adolescents and the reasons for substance 
abuse varied. For example, some started using drugs or alcohol socially with friends 
(D’Amico & McCarthy, 2006), while others abused substances to calm their mood or 
reduce anxiety. Another set of the participants experienced drugs and alcohol abuse as 
part of their family home life (Hops, Tildesley, Lichtenstein, Ary, & Sherman, 1990; 
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Kandel, Griesler, Lee, Davies, & Schaffran, 2001; Lieb et al., 2002). Others attributed 
their substance abuse problems to the sexual, physical, or emotional abuse they suffered 
as children (Hyman, Garcia, & Sinha, 2006; Leenerts, 1999; McCauley et al., 1997; 
Widom, Marmorstein, & White, 2006; Widom, Weiler, & Cottler, 1999). 
The participants of this study spoke about the escalation of their substance abuse. 
For some, the escalation occurred over a period of years, but for others it was very rapid 
acceleration. Many revealed alcohol was a starting point that later escalated to abuse of 
harder substances. They described how they only snorted or smoked cocaine or heroin, 
but then progressed to injecting the drugs. This finding in the study supports other studies 
that concluded it is necessary to move on to injecting a drug because the high can no 
longer be obtained by snorting or smoking it (Doherty et al., 2000). In addition, some 
said they began to use other drugs when they were under the influence of alcohol 
(Doherty et al., 2000). The results of this study are consistent with others who have found 
substance abuse progressed over time (Andrews, Tildesley, Hops, Duncan, & Severson, 
2003; Duncan, Duncan, & Hops, 1998). In addition, other studies have concluded 
substance abuse continued and even escalated after receiving the diagnosis of HIV 
infection (Von Unger & Collins, 2005). 
Polysubstance abuse was a major problem for the participants in this study, 
affecting 94% of the sample. In many instances, drugs are used in combination to reduce 
the side effects of one drug (e.g., use of cocaine to reduce withdrawal effects of heroin), 
to enhance the high, or to obtain a different high (Leri, Bruneau, & Stewart, 2003). The 
National Survey on Drug Use and Health (2005) showed that 3.3 million out of the 22.2 
million persons 12 years or older with substance abuse disorders were dependent on a 
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combination of alcohol and illicit drugs. Polysubstance abuse poses a significant problem 
for individuals in substance abuse treatment and recovery. Grella and Joshi (1999) found 
those entering substance abuse rehabilitation were more likely to be dependent on 
multiple substances rather than alcohol alone. Further, polysubstance abuse is a reason 
for dropout in substance abuse rehabilitation or failed outpatient treatment (Chatham, 
Rowan-Szal, Joe, & Simpson, 1997; Mammo & Weinbaum, 1993; Shah et al., 2006). 
Substance Abuse Relapse, Triggers, and Recovery 
In this study, five participants were actively abusing alcohol or a combination of 
drugs and alcohol and 26 were in various stages of recovery ranging from two months to 
17 years. The participants of this study said they had been in substance abuse treatment 
programs multiple times. The findings from this study show the high rates of substance 
abuse recidivism and the fragile nature of recovery. Other research also shows that many 
with substance abuse problems spend years in a pattern of relapse, treatment, and 
recovery (Scott, Foss, & Dennis, 2005). Approximately 1.9 million people entered 
substance abuse treatment programs in the US in 2005 (Office of Applied Studies, 2006). 
Of those admitted, 62% entered an outpatient treatment program, 21% entered a 
detoxification program, and 17% entered a residential treatment program. Of those 
admitted to a substance abuse treatment program, approximately 44% completed 
treatment (Office of Applied Studies, 2006). Many relapse to substance abuse soon after 
treatment (Gossop, Stewart, Browne, & Marsden, 2002). In most instances, those who 
attend substance abuse rehabilitation return to the same environment in which they came 
from prior to the treatment. By returning to the same social network after substance abuse 
rehabilitation, the individual is at risk for returning to injection drug use (Costenbader, 
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Astone, & Latkin, 2006; Latkin, Knowlton, Hoover, & Mandell, 1999; Latkin et al., 
1995; Sun, 2007). Sun (2007) found that when women return to the same environment in 
which they came from before substance abuse treatment, they were likely to relapse 
without resources such as employment, family support, and housing security. The Drug 
Abuse Treatment Outcome Study (DATOS) (Grella, Hser, & Hsieh, 2003), which 
followed a cohort of cocaine abusers (N = 347) for five years, found that 44% of the 
study participants required substance abuse treatment again on average 2.6 years 
following discharge from treatment. Instead of viewing relapse as a failure, it can be 
viewed as part of the recovery process (Sun, 2007). The relapse can be used as a time for 
education in order to understand the events leading up to the relapse. Therapies for 
relapse recovery can include increasing the individual’s involvement with positive social 
networks, teaching or practicing behavioral modification skills, and strengthening coping 
strategies (Carroll & Rounsaville, 2006). It has been suggested that a post rehabilitation 
discharge monitoring program should include quarterly checkups to shorten the time 
between relapse and the return to a rehabilitation program (Scott, Dennis, & Foss, 2005; 
Scott, Foss, & Dennis, 2005). Furthermore, long-term follow-up is needed to address the 
chronic nature of substance abuse disorders (Grella et al., 2003). 
Many of the participants in this study could identify the triggers that stimulated 
the desire to abuse drugs and/or alcohol. In particular, stressful life events (especially the 
death of a loved one) and the use of alcohol were mentioned by participants in this study. 
In two qualitative studies (Von Unger & Collins, 2005; Sun, 2007), women revealed that 
stressful life events, including the death of a loved one, caused them to relapse. 
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Several participants, nearly all women, acknowledged their partners influenced 
their substance abuse practices. In many instances, these negative relationships were 
triggers for some women to relapse. The women in this study said they were controlled 
by their male partner and would do anything to maintain the relationship, including 
distributing drugs, stealing, and participating in prostitution. Others have confirmed that 
those with substance abuse issues have a tendency to have social and familiar networks 
that have similar characteristics and tend to perpetuate substance abuse behaviors 
(McCrady, 2006; Sherman, Latkin, & Gielen, 2001). Also, research is beginning to 
identify substance abuse similarities in concordant adult couples (Cavacuiti, 2004). It has 
also been found that individuals tend to partner with others with similar substance abuse 
disorders (Low, Cui, & Merikangas, 2007). Still other researchers have found that women 
tend to emulate their male partner’s substance abuse patterns (Amaro & Hardy-Fanta, 
1995; Daniulaityte, Carlson, & Siegal, 2007; Sherman, Latkin, & Gielen, 2001). 
Furthermore, women are likely to share injection equipment if their injection partner is: 
(1) their significant other (p < .05), (2) a family member, friend, or acquaintance  
(p < .05), or (3) someone they have shared injection equipment with before (p < .001) 
(Tortu et al., 2003). Women share drug injection equipment within a larger social 
network that includes both men and women rather than just with their significant other 
(Doherty et al., 2000; Sherman, Latkin, & Gielen, 2001). On the other hand, a woman 
who injects drugs with her partner can be isolated, especially if that partner injects drugs 
and controls the relationship (Rhodes & Quirk, 1998). Moreover, some evidence shows 
that women use drugs to relieve negative emotions associated with destructive 
relationships with men (Leenerts, 1999; Miller, 1999; Sun, 2007). In a qualitative study 
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by Sun (2007), women said they lacked a personal identity and their self-worth was tied 
to the success or failure in their relationships with men. In addition, the women reported 
they relapsed for a variety of reasons such as feeling abandoned by their partner, having 
low self-esteem, or a perceived lack of support from authoritative systems (i.e., child 
welfare, drug treatment centers, probation monitoring systems). In comparison to the 
current study, the women in the study by Sun (2007) were younger (M = 34) and were 
addicted to methamphetamines where in the current study the women were older  
(M = 42) and addicted to heroin, alcohol, and cocaine respectively. Similarly, Sun (2007) 
found many (49%) of the women abused multiple illicit substances, primarily 
methamphetamines, heroin, cocaine, and alcohol. Despite the differences in the age and 
drug of choice between the samples, there were several similarities with the present 
study. The women in both studies reported interpersonal relationships with significant 
others, negative emotions (especially low self-esteem), and stressful life events 
(especially the death of a loved one) were all triggers for relapse. 
The majority of the participants had experienced periods of sobriety. Some said 
they wanted to make others proud they were sober; while others spoke about the skills 
and techniques they used to stay sober. For the few participants who had accomplished 
long-term sobriety, self-acceptance was essential. They also said it was important that 
they took control of their sobriety and maintained that sobriety for themselves. Many 
used support groups in order to help maintain their sobriety. Other techniques included 
surrounding themselves with others who did not have substance abuse problems, being 
reunited with family and friends, staying out of destructive relationships, and keeping 
busy with enjoyable activities. These findings are similar to Flynn and colleagues’ (2003) 
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assertion that those who achieved long-term recovery (five years or more) are 
significantly more likely to be in a long-term recovery support program (p < .0001), have 
support from family (p < .05), have a sense of responsibility to self (p < .0001), and 
viewed self as a productive member of society (p < .0001). In addition, those in long-term 
recovery had higher levels of spirituality than those who were still struggling with 
substance abuse (p < .01) (Flynn et al., 2003). In the current study, many of the 
participants felt their faith and spirituality helped them to stay clean and sober. 
Twelve-Step Language 
Many of the participants of this study used language and terms from 12-Step 
programs such as Alcoholics Anonymous or Narcotics Anonymous. These 12-Step 
programs are based on a fundamental belief that the person is powerless over drugs or 
alcohol and that there is a God or a Higher Power that can restore sanity. Faith-based 
substance abuse programs have been in existence for over a hundred years in the US. In 
the early 1900s, the Universal Prayer was recited for 15 days in anti-opium and anti-
alcoholic meetings as part of protection against the “evils” of opium and alcohol 
consumption (Crafts, Crafts, Leitch, & Leitch, 1909, p. 12). In today’s 12-Step programs, 
a person manages their sobriety one day at a time and asks God, or their Higher Power, to 
give them strength to overcome substance abuse (Alcoholics Anonymous, 2007; 
Narcotics Anonymous, 2007). Some have found that faith and spirituality are important 
components of substance abuse treatment (Arnold, Avants, Margolin, & Marcotte, 2002). 
Pardini and colleagues (2000) found that patients with high levels of spirituality could 
expect higher levels of social support, more resilience to stress, and a lower level of 
anxiety.  
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Some of the participants also spoke about how their substance abuse is telling 
them it is okay to use and they are powerless over the drugs and alcohol. The language 
threaded throughout the interviews suggested that many rely on others such as God or a 
Higher Power as part of their motivation for their substance abuse recovery. Despite 
having gone through rehabilitation, five participants were active substance abusers and 
six were in a residential treatment facility at the time of the interview. These data suggest 
that many participants in this sample continue to struggle with substance abuse issues. 
Alcohol as a Major Problem in HIV/HCV Co-Infection 
Many of the participants identified alcohol as a problematic substance. One 
participant admitted he lied to his healthcare provider about his alcohol consumption 
during and after HCV treatment. He drank alcohol during the treatment and continued 
drinking heavily after treatment. He, therefore, did not achieve SVR and treatment was 
aborted at 12 weeks. Active alcohol abuse has been identified as a major barrier to 
receiving HCV treatment (Adeyemi et al., 2004; Nunes et al., 2006). Alcohol 
consumption (more than 30 grams/day) has been associated with failure to respond to 
pegylated interferon and ribavirin in patients with HCV mono-infection (Chang et al., 
2005). On the other hand, some studies suggest that alcohol consumption is not an 
absolute contraindication to HCV treatment, but no safe levels of consumption have been 
established (NIH, 2002). Treatment of alcohol abuse is recommended prior to HCV 
treatment, but it should not impede a pre-treatment evaluation (NIH, 2002). 
In the US in 2005, 45% of those with an alcohol disorder had a secondary drug 
abuse disorder (Office of Applied Studies, 2006). In this sample, five out of the six 
individuals in a residential treatment facility said they had a problem with alcohol. 
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Because of their substance abuse, none of the individuals in the residential treatment 
facility were considering HCV treatment at the time of the interview. Unfortunately, 
limited data exists that describes the experiences of patients with active alcohol abuse and 
with HIV/HCV co-infection (Nunes et al., 2006; Sherman, 2003; Sherman, 2007). In 
addition, there is limited information on how active alcohol abuse affects patient 
decision-making regarding HCV treatment (Fraenkel et al., 2005). Therefore, moving 
patients with HIV/HCV co-infection towards HCV treatment requires a greater 
understanding of the interplay between alcohol consumption and the decision-making 
process (Nunes et al., 2006; Sherman, 2003; Sherman, 2007). 
HCV Treatment Decision-Making 
The second goal of this study was to gain a preliminary understanding of how 
substance abuse experiences can affect HCV treatment decision-making. Twenty-one 
participants in this study sample had not undergone HCV treatment, although over half 
had undergone a pre-treatment evaluation that included a liver biopsy. In this sample, ten 
participants (7 men and 3 women) had previously undergone HCV treatment. It is not 
clear why, in this sample, greater numbers of men had been evaluated and treated for 
HCV infection. A partial explanation may be that more women were in a residential 
treatment facility and were marginally housed compared to men. In addition, four women 
in this study (compared to no men) were scheduled to begin HCV treatment, but backed 
out for unknown reasons. Because of these obvious gender-related differences, further 
research is needed to explore the reasons gender plays a role in HCV evaluation and 
treatment. 
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The participants described fears regarding substance abuse and HCV treatment. 
That finding in this study supports others who found fear as a significant barrier to HCV 
treatment (Fleming et al., 2003; Fleming et al., 2005). Several participants said their 
initial fear was of handling the needles used to inject interferon. These findings support 
others who found fear can be associated with the act of self-injecting interferon - which 
might trigger relapse of injection drug use (Fishbein et al., 2004). Because of this fear, 
some participants considering HCV treatment knew that having access to needles in their 
home, or handling the needles, put their sobriety at risk. By recognizing this fear and 
identifying the risk the needles pose to their sobriety, the participants were able to control 
triggers associated with relapse. Identifying and acknowledging triggers in relapse 
prevention is an important aspect in substance abuse recovery (Hoffman, Jones, Caudill, 
Mayo, & Mack, 2003). 
While most of the participants of this study said they had a good relationship with 
their healthcare provider and felt well prepared for HCV treatment, some suggested a 
support group would be helpful during the decision-making process and while they were 
going through HCV treatment. Similarly, Fraenkel and colleagues (2006) found the 
participants in their study felt it would be helpful to have had the opportunity to attend a 
support group that included family members when they were preparing for HCV 
treatment. 
Some participants in this study chose to take an active role in the decision-making 
process, others did not. This is an indication that healthcare providers need to be 
proactive to ensure HIV/HCV co-infected patients be evaluated for HCV treatment. The 
decision to move forward with HCV treatment is complex process for those with 
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substance abuse issues and an HIV/HCV co-infection. Some evidence shows more 
individuals with an HIV/HCV co-infection are receiving referrals for an evaluation for 
HCV infection (Mehta et al., 2006). Despite the referrals for an evaluation, there are still 
low reported HCV treatment rates in this population (Mehta et al., 2006). Consequently, 
due to low HCV treatment rates in HIV/HCV co-infected patients, a greater 
understanding of the factors contributing to patient treatment decision-making is still 
needed (Wagner & Ryan, 2005). 
Substance Abuse Experiences within Interactive Decision-Making Framework 
This is the first study to use the Interactive Decision-Making Framework (Pierce 
& Hicks, 2001) to ascertain whether they fit best with patient or contextual factors. The 
interactive decision-making framework has been used to study patients’ decision-making 
processes regarding hemodialysis treatment among (1) Taiwanese adults (Lin et al., 
2005), (2) in women during labor (Carlton et al., 2005), and (3) women with breast 
cancer (Budden et al., 2003).  No study has been identified within the literature 
documenting the use of this framework to examine substance abuse experiences in 
HIV/HCV co-infected patients. 
In the present study a variety of both patient and contextual factors emerged 
during the analysis. The patient factors included substance abuse choice, decision values, 
and preferences for participation in healthcare choices. Several participants recognized 
they had a choice when it came to their substance abuse habits. Some said they chose to 
abuse drugs or alcohol because it made them feel better, despite knowing the health risks 
involved with substance abuse. Others chose sobriety over substance abuse. This was 
especially important in those who were undergoing or had completed HCV infection 
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treatment. The participants who were currently undergoing or had completed HCV 
infection treatment believed being clean and sober was an important decision to make 
before committing to HCV infection treatment. The contextual factors included patient – 
provider interactions. Most of the participants felt supported by their healthcare provider. 
In addition, many relied on their treatment decisions to be made by the providers. 
Based on the available data, it is unclear whether substance abuse experiences fit 
best within patient or contextual factors. In addition, it is unclear if this framework is 
ideal for examining the decision-making processes in patients with HIV/HCV co-
infection face with HCV treatment decisions. Further work is needed to understand 
substance abuse and decision-making behaviors. 
Study Limitations 
This study was limited by several factors related to research using secondary data. 
First, the data were not collected for the purpose of answering these specific research 
questions, limiting the researcher’s ability to fully explore some of the themes and sub-
themes. Second, the researcher was unable to conduct follow-up interviews with the 
participants. By meeting with the participants in a follow-up, face-to-face interview, 
information redundancy could have been pursued to more fully define the link between 
substance abuse and HCV treatment decision-making. In spite of this limitation, the data 
did reveal rich descriptions of the substance abuse experiences and some preliminary data 
on how these experiences impacted patient treatment decision-making. 
Furthermore, the secondary aim to determine if substance abuse fits best with 
patient or contextual factors within the framework was not uncovered. A partial 
explanation may be likely due to the differences in the parent study organizing 
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framework and the organizing framework used in this study. A study designed to 
incorporate the Interactive Decision-Making Framework (Pierce & Hicks, 2001) may 
uncover where substance abuse experiences fit within the framework. 
Finally, all of the participants in this study had a history of substance abuse so the 
results should be interpreted with caution in those with HIV/HCV co-infection without a 
history of substance abuse. 
Implications and Recommendations for Future Research 
Findings from this study will be useful to develop knowledge related to substance 
abuse in HIV/HCV co-infected adults. Implications for future research with HIV/HCV 
co-infected individuals emerged from these data. The results suggest:  
1. There is a need to understand factors associated with substance abuse initiation in 
children, adolescents, and young adults. Nearly half of the participants of the 
current study started abusing drugs or alcohol as children or adolescents. In 
addition, a greater understanding of the decision-making processes regarding drug 
abuse initiation in children, adolescents, and young adults is needed. Research is 
needed to develop or enhance targeted interventions to help mitigate risk-taking 
behaviors associated with substance abuse in children, adolescents, and young 
adults. 
2. Further research is needed to understand issues surrounding substance abuse 
triggers and relapse in individuals with an HIV/HCV co-infection. In the current 
study, multiple factors influenced substance abuse relapse. Both men and women 
in this study had a high rate of substance abuse recidivism. It is important to study 
why so many individuals fail substance abuse rehabilitation, including 
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understanding the factors surrounding substance abuse relapse such as social 
networks, gender issues, and cultural differences. 
3. Further research is needed to understand the issues that women face during 
substance abuse and the recovery process. In the current study women were 
particularly vulnerable to being in a destructive relationship with a partner and 
many placed a significant amount of emphasis on their personal well being on the 
success or failure of that relationship. A greater understanding of how emotions, 
social networks, and personal relationships affect substance abuse in women is of 
particular importance. 
4.  Additional work is needed to understand polysubstance abuse issues in 
individuals with HIV/HCV co-infection. While it was a major problem for nearly 
all of the participants in the present study, it was not fully uncovered. A study 
designed specifically to understand the experiences and factors associated with 
polysubstance abuse in HIV/HCV co-infected adults is needed. 
5. Further work is needed to understand patient decision-making related to HCV 
treatment in those with an HIV/HCV co-infection. In the current study, some of 
the patient and contextual factors emerged during analysis, however not enough to 
reach information redundancy regarding how substance abuse affects HCV 
treatment decisions. A study designed using the Interactive Decision-Making 
Framework (Pierce & Hicks, 2001) may uncover patient and contextual factors 
related to substance abuse and HCV treatment decision-making. Data from this 
study also showed gender differences in those who had undergone HCV 
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treatment. It will be important to understand the differences between men and 
women regarding the factors influencing HCV treatment decisions. 
Finally, some practical findings that emerged from the study data that could be 
applied to research and practice include the following: 
1. Early identification and treatment of substance abuse in children, adolescents, and 
young adults is crucial to prevent the spread of HIV/HCV co-infection. 
2. Aggressive substance abuse treatment of HIV/HCV co-infected individuals is 
essential to improve outcomes. 
3. Substance abuse recovery is a long-term process and requires monitoring for 
potential relapse. Therefore, patients should be assessed frequently for stressful 
life events (especially the death of a loved one) and alcohol consumption that 
could trigger relapse. 
4. Provider evaluation for possible fear and misconceptions about substance abuse 
and HCV treatment during clinical visits and throughout HCV treatment in order 
to alleviate possible barriers for evaluation and treatment. 
5. Patients with HIV/HCV co-infection should be encouraged to undergo HCV 
evaluation according to clinical treatment guidelines (i.e., liver biopsy, laboratory 
work, HCV genotyping) in order to move patients towards HCV treatment if it is 
needed. 
Study Conclusion 
Results of this study provided a rich description of the substance abuse 
experiences of HIV/HCV co-infected adults. Five major themes emerged describing 
substance abuse evolution, substance abuse relapse, reconstructing life after substance 
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abuse, HCV treatment issues, and getting clean. The linkage between substance abuse 
and HCV treatment decision-making was explored and included patient and contextual 
factors that linked decision-making to substance abuse issues. Further work is needed to 
fully understand this linkage. This study adds to the knowledge of substance abuse 
experiences in HIV/HCV co-infected adults. In addition, this study offers a preliminary 
examination of how substance abuse experiences influence HCV treatment decision-
making. These findings will also be helpful to healthcare providers and to those who 
develop HCV treatment guidelines for individuals with substance abuse disorders and 
HIV/HCV co-infection. Further work is needed to understand substance abuse issues in 
children, adolescents, and young adults to reduce the transmission risks of HIV/HCV co-
infection. Relapse and recovery are fragile in nature especially in HIV/HCV co-infected 
adults. The decision-making process is influenced by substance abuse experiences, 
however more research is needed to uncover specific factors influencing these decisions. 
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 Tables and Figures 
Table 1. Decision-Making Qualitative Literature (HIV Focus) 
Study Specifics Findings / Outcomes Implications What is 
Not 
Known 
Author / Year:  
*Kremer / 2006 
Sample:  
N = 79 
Location: Florida 
Mean age: 42.03 
Gender: 35.4% Female 
Ethnicity: 
 AA: 41.8% 
 Latino: 27.8% 
 White: 24.1% 
 Other: 6.3% 
Drug use past month: 
 Marijuana: 26% 
 Cocaine: 16.3% 
 Other drugs: 16.6% 
Method:   
Cross Sectional 
Qualitative Sub-study 
Qualitative Content 
Analysis 
Convenience sample 
Purpose of study: 
How persons living with 
AIDS make treatment 
decisions 
Ten Themes: 
1.  Surrogate Markers 
2.  Better Qualitative 
of life 
3.  Resistance Beliefs 
4.  Mind Body Beliefs 
5.  Drug Side Effect 
6.  Easy to Take 
7.  Spirituality/World 
View 
8.  Resistance Testing 
9.  HIV/AIDS 
symptoms 
10.  Preference for 
Alternative 
Medicine  
Patients not taking 
antiretroviral therapy 
(ART) preferred 
complementary/alternat
ive medicine (r = .43, p 
= .001) 
Perceived a better QOL 
without ART (r = .32, p 
< .040) 
Weighted Avoidance of 
adverse effects of ART 
more heavily (r = .24, p 
= .030) than patients 
taking ART 
Decisions not to take 
ART was dependent 
on not having a 
partner, having 
health insurance, 
individual beliefs 
about ART, 
complementary/alter
native medicine, 
spirituality, mind-
body connection 
HIV positive patient 
placed more weight 
on alternative 
medicine, avoiding 
adverse effects of 
ART and perceived a 
better QOL by not 
taking ART. 
How 
strongly 
the 
necessity 
of taking 
ART was 
stressed by 
the HCP 
How 
substance 
abuse, 
mental 
health 
issues, 
AIDS 
diagnosis 
would 
effect 
decisions 
to take or 
not to take 
ART in 
this 
sample 
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Study Specifics Findings / Outcomes Implications What is 
Not 
Known 
Table 1. Decision-Making Qualitative Literature (HIV Focus) (continued) 
Author / Year:  
Misener & Sowell, 1998
Sample:  
N = 22 
Location: Rural 
Southeastern U.S. 
Mean age:  31.5 
Age Range:  20 - 43 
Gender: Women 
Ethnicity: 
 AA: n = 18 
 White: n = 4 
Method:   
Two Focus Groups 
Convenience sample 
Four Themes: 
1.  Influence of HCP 
- Most of those on 
AZT reported most 
had a good 
relationship with 
HCP and they felt 
included in their 
health care decisions 
- Many of the 
women lacked trust 
in their HCP and felt 
they were “guinea 
pigs” and felt the 
HCP had to 
Decision about AZT 
were influenced by 
HCP, lacked trust 
was the most 
significant finding 
around the 
acceptance of and 
adherence to 
treatment. Continued 
efforts to educate and 
provide clear 
information about 
medication. Many 
did not believe in 
taking medications 
Not 
discussed 
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Table 1. Decision-Making Qualitative Literature (HIV Focus) (continued) 
Study Specifics Findings / Outcomes Implications What is 
Not 
Known 
Purpose of study: 
To explore factors that 
influence decisions 
about ART in HIV-
infected women 
prescribe the AZT to 
keep their license, 
felt they were part of 
some experiment 
such as Tuskegee. 
- Feared losing their 
HC services or being 
placed in jail if they 
refused AZT if they 
became pregnant 
- were not honest 
about adherence to 
medications 
2.  Beliefs about ART 
- desire to avoid 
drugs due to beliefs 
about not taking 
medication 
- felt the treatment 
was not helpful or 
effective and 
possibly dangerous 
- some women 
believed that AZT 
helped them have 
HIV negative babies 
3.  Side effects - 
negative side effects 
impacted their 
decisions to take 
AZT 
4.  Peer & Family 
- influenced by 
information received 
from peers and 
family 
- were more likely to 
trust a women, 
especially their 
mothers 
and had significant 
fear about side 
effects. It is 
important to support 
and educate patients 
throughout the 
medication ART 
Author / Year:  
*Marelich / 2002 
Four Themes: 
1.  Joint decision-
Various levels of It is not 
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Study Specifics Findings / Outcomes Implications What is 
Not 
Known 
Sample:  
N = 39 
Location: California 
HIV clinic 
Mean age: 40.9 
Age range: 33-54 
Gender:  
 Female: 21%
 Male: 69%
Ethnicity: 
 AA: 44% 
 White: 39% 
 Latino / other: 12% 
Method:   
Four Focus Groups  
Qualitative 
Convenience sample 
Purpose of study: 
To assess Hiv-infected 
adult patients 
involvement in ART 
decision with HCP 
making - work with 
HCP as part of a 
team 
2.  Patients taking 
control and making 
up their own minds 
- takes an assertive 
approach 
- decides treatments 
based on 
recommendations 
3.  Initial passivity then 
involvement - as the 
patient learned about 
HIV they were more 
involved in decisions 
4.  Patients as 
knowledge gatherers 
- gathered 
knowledge about 
HIV from many 
sources (peers, other 
professionals, 
family, media, other 
HIV positive 
individuals) 
involvement in 
health care decisions 
and had good 
working relationships 
with their providers 
and changed HCP if 
they felt they were 
not receiving optimal 
care 
Patients were passive 
initially and as the 
patients become 
more knowledgeable, 
they began to make 
own treatment 
decisions and take a 
more assertive 
approach to what 
they wanted 
known 
how the 
nature of 
the sample 
impacted 
the 
findings 
(i.e., 
strong and 
em-
powered). 
How 
would 
those with 
more 
advanced 
HIV/AIDS 
disease be 
involved 
in 
decision- 
making? 
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Study Specifics Findings / Outcomes Implications What is 
Not 
Known 
Table 1. Decision-Making Qualitative Literature (HIV Focus) (continued) 
Author / Year: 
*Laws / 2000 
Sample:  
N = 61 
n = 25 Sub Analysis 
Location: 
Massachusetts 
Language: 
 English: n = 46 
 Spanish: n = 15 
Mean age: 39.3 
Age Range: 24-57 
Gender:  
 Female: 25% 
 Male: 75% 
Ethnicity: 
 AA: n = 7 
 White: n = 24 
 Latina: n = 29 
 Portuguese: n = 1 
----------------------------- 
Sub-Analysis Group 
n = 25 
Gender:  
 Female: 32% 
 Males:  68% 
Ethnicity: 
 AA: n = 3 
 White: n = 9 
 Latina: n = 12 
 Portuguese: n = 1 
Method:   
Qualitative  
Convenience Sample 
Focus group (n = 8) to 
develop interview tool 
Random Selection to be 
in Sub-Analysis group 
(n = 25) 
Three Themes: 
1.  Beliefs about viral 
resistance and 
skipping doses 
(some knew that 
missing or skipping 
does of ART had 
negative 
consequences, some 
believed that the 
resistance was 
changes in their 
body rather than the 
virus) 
2.  Patterns of Non-
adherence 
- Several patients 
initially stated they 
did not miss 
medications but later 
in the interview 
admitted missing 
doses frequently, 
patients stopped 
treatment without 
telling their HCP, 
failed to have 
prescriptions filled, 
took “drug holidays” 
to cleanse the body, 
not taking 
medications during 
sleep/nap periods, 
sets own schedule 
for taking 
medications,  
substance abuse 
(caused respondents 
to forget about HIV 
and medications and 
focus was on 
Only 4 of 25 were 
adherent with 
medications. 
Many factors about 
decisions to take or 
not take medications 
due to a variety of 
factors (forgetting, 
stopping, drug 
holidays, sleep 
patterns, side effects, 
drug addiction). 
What the 
HCP told 
the patient 
about 
adherence, 
med-
ications, 
assessment 
of 
adherence 
to 
medication 
regimens. 
Complex behavior 
surrounding 
decisions about 
taking ART. 
117 
Table 1. Decision-Making Qualitative Literature (HIV Focus) (continued) 
Study Specifics Findings / Outcomes Implications What is 
Not 
Known 
Purpose of study: 
To describe how people 
with HIV understand the 
experience the problem 
of adhering to ART 
regimens using the Sub-
Analysis Group 
obtaining drugs and 
did not want the HIV 
medications to 
interfere with high) 
3.  Relying heavily on 
HCP advice when 
deciding about ART 
Author / Year: 
*Moser / 2001 
Sample:  
N = 25 
Location: Southern US 
Mean age: 38 
Age Range: 22-57 
Gender: Women 
Ethnicity: 
 AA: n = 24 
 White: n = 1 
Method:   
Qualitative 
Four Focus Groups 
Purpose of study: 
To identify and discuss 
their concerns and needs 
related to their HIV / 
AIDS and substance 
abuse 
Five Themes: 
1. AIDS as a life 
altering event 
2. Spirituality 
3. Mental health issues 
4. Barriers to HC 
services 
Coexisting substance 
abuse and HIV is 
complex 
comorbidities for 
these women 
How 
substance 
abuse 
impacts 
treatment 
decision-
making 
and how 
providers 
impact 
treatment 
decision-
making in 
HIV-
infected 
women 
5. Environmental 
influences 
 
Note 1: * First Author Listed 
Note 2: Abbreviations: HCV = hepatitis C virus, HCP = healthcare provider, ART = 
antiretroviral therapy, QOL = Quality of life, AA = African American, DPH = 
Department of Public Health, HC = health care 
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Table 2. Decision-Making Qualitative Literature (HCV Focus) 
Study Specifics Findings / Outcomes Implications What is 
Not 
Known 
Author / Year: 
*Fraenkel / 2005 
Sample:  
N = 40 
Location: Connecticut 
Mean age: 51.5 
Age Range 40-60 
Gender:  20% Female 
Ethnicity: 82% White 
Education: 59% had 
greater than HS 
education 
Employment: 55% 
employed 
Method:  
Eight focus groups 
Eligible to participate if 
had a liver biopsy and 
had HCV treatment 
undergoing treatment, 
or had been offered 
treatment but refused 
Separate groups for 
those with substance 
abuse, mental illness 
and those who did not 
have either 
comorbidities 
Purpose of study: 
To ascertain patients 
perspective about the 
factors that influence 
decisions as they 
consider HCV treatment 
Six Themes: 
1. Consideration of risk 
benefit tradeoffs 
(how the 
risks/tradeoffs of 
HCV treatment 
influenced decisions 
2. Protected Values 
(Strong personal 
preferences one way 
or the other) 
3. Heuristics (following 
decision to avoid 
regret) 
4. Conceptualization of 
illness (how the 
patient sees the 
illness either being 
cured or living with 
it) 
5. Social Issues 
(family, work, 
responsibilities) 
6. Physician’s 
recommendations 
(this was very 
important in either 
decision to take or 
not to take HCV 
treatment) 
Decisions are based 
on many factors 
besides risks and 
tradeoff values of 
HCV medications / 
treatment 
HCP should help 
facilitate decision-
making through 
education 
(understanding 
treatment, side 
effects, potential 
outcomes)  
Respect patient 
values and decisions 
Know that treatment 
decisions may be 
strongly influenced 
on HCP 
recommendations 
Unable to 
infer 
import-
ance of the 
factors via 
quan-
titative 
measure-
ment 
 
Note 3: * First Author Listed 
Note 4: Abbreviations: HCV = hepatitis C virus, HCP = healthcare provider, ART = 
antiretroviral therapy, QOL = Quality of life, AA = African American 
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 Table 3. Demographic Characteristics of the Sample 
Characteristic Frequency Percentage Value 
Male 16 51.6 Gender Female 15 48.4 
White 18 58.1 
Hispanic 8 25.8 
African American 4 12.9 Race 
American Indian 1 3.2 
Single 16 51.6 
Living with partner 5 16.1 
Divorced 5 16.1 
Married 3 9.7 
Separated 1 3.2 
Marital Status 
Other 1 3.2 
HS/GED 22 71 Education No HS/GED 9 29 
Apartment 17 54.8 
Own Home 7 22.6 
Homeless 4 12.9 Housing Situation 
Other 3 9.7 
Not Working 21 67.7 
Work Part Time 3 9.7 
Work Full Time 3 9.7 
Volunteer 3 9.7 
Work Status 
Other 1 3.2 
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Table 4. Clinical Characteristics of the Sample 
Characteristic Frequency (n) Percentage Value 
1 19 76 
2 1 4 
3 3 12 
4 2 8 HCV Genotype 
Missing genotype 
information 6 19 
Range: 550-18,900,000 25 80.6 Most Recent HCV/RNA Missing HCV/RNA 6 19.4 
Asymptomatic 12 38.7 
Symptomatic 8 25.8 HIV Status 
AIDS 11 35.5 
Length of Time with 
HIV diagnosis in Years Mean, range:13.7, 2-20 31 100 
On HIV Treatment 25 80.6 HIV Medications Not on HIV Treatment 6 19.4 
Mean, range: 468.5, 104-
1056 28 90.4 Most Recent CD4 
Missing CD4  3 9.6 
Undetectable HIV RNA  <75 6 19.3 
Mean, range: 8400, 50-
69,307 26 83.9 HIV/RNA 
Missing HIV/RNA 5 16.1 
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Table 5. Self Reported Problematic Use of Specific Substances 
Frequency (n) Percentage Substance 
Heroin 27 87.1 
Cocaine 26 83.9 
Alcohol 24 77.4 
Speedball 21 67.7 
Marijuana 20 64.5 
Crack 15 48.4 
Tranquilizers 9 29.0 
Other Drugs (not identified 
by participant) 9 29.0 
Street Methadone  4 16.1 
Oxycontin 3 9.7 
Amphetamines 4 12.9 
Street Morphine 2 6.5 
Ecstasy 2 6.5 
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Table 6. Self Reported Most Problematic Use of Specific Substances 
Frequency (n) Percentage Most Problematic Substance 
Heroin 15 48.4 
Alcohol 6 19.2 
Heroin and cocaine 3 9.6 
Cocaine 2 6.5 
Heroin and alcohol 1 3.2 
Speedball 1 3.2 
All of the Substances 1 3.2 
Missing Data 2 6.5 
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Table 7. Self-Reported Frequency of Problematic Substances 
Self-Reported Numbers of 
Problematic Substances Frequency (n) Percentage 
9 Substances 2 6.4% 
8 Substances 3 9.6% 
7 Substances 2 6.4% 
6 Substances 9 29% 
5 Substances 5 16.1% 
4 Substances 3 9.6% 
3 Substances 3 9.6% 
2 Substances 3 9.6% 
1 Substance 2 6.4% 
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Table 8. Mental Illness Related to Diagnoses, Hospitalizations, Medications, and 
Suicide Attempts 
Frequency (n) Percentage Diagnosis 
Any Mental Illness Diagnosis 27 87.1 
Depression 21 67.7 
Anxiety 18 58.1 
Bipolar Disorder (manic/depressive 
illness) 7 22.6 
Obsessive Compulsive Disorder 7 22.6 
Panic Disorder 6 19.4 
Post Traumatic Stress Disorder 
(PTSD) 5 16.1 
Personality Disorder 1 3.2 
Other (schizoid type) 1 3.2 
Schizophrenia 0 0 
Hospitalization to treat mood or 
Mental Illness 9 29.0 
Currently taking medications to 
treat mood or mental illness 20 64.5 
Prior suicide attempts 12 38.7 
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Appendix A 
Parent Study Interview Guide 
Questions Probes 
What has the experience of having 
Hepatitis C infection been like for you? 
Probes: How did you find out? 
What information were you given? Was it 
helpful? What was your initial reaction 
versus current feelings? What supports do 
you have? 
How has the quality of your life been since 
you found out that you had Hepatitis C? 
Probes: How was the quality of your life 
before you found out you had HCV? Has it 
changed? In what way? 
What symptoms do you have that you 
believe are related to Hepatitis C? 
Probes: What are these symptoms? How 
severe are they? Why do you think they are 
related to HCV? How do you manage these 
now? How do these affect your ability to 
live day to day? 
Have you had any problems with your 
mental health? 
Probes: Any problems feeling down or 
depressed? How do these symptoms 
compare to last week, last month, last year? 
Have you been anxious or uptight recently? 
How do theses symptoms compare to last 
week, last month, last year? What helps 
you to manage these symptoms? 
Have you had any problems with drug or 
alcohol use? 
Probes: How do these problems compare to 
your experiences in the past? What is the 
most problematic substance for you? What 
helps you to manage? 
How could your doctor or nurse help you 
manage this experience better? 
Probes: Has your healthcare provider given 
you enough information about HCV? What 
information would you like? How has 
he/she been helpful? Not helpful? 
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Appendix B 
Parent Study HCV/HIV Co-infection Baseline Demographic and Clinical Cofactor Sheet 
Study ID #  ___ ___ ___ 
 
Age in Years              __________ 
 
Gender  ( ) Male = 0 
   ( ) Female = 1 
   ( ) Transgender = 3 
 
Ethnicity  ( ) Hispanic/Latino = 1 
   ( ) non-Hispanic/Latino = 0 
 
Race   ( ) American Indian = 1 
   ( ) Asian = 2 
   ( ) Black/African American = 3 
   ( ) Native Hawaiian/PI = 4 
   ( ) White = 5 
   ( ) Other: _________ = 6 
 
Years of Education ____________months 
 
HS/GED  ( ) no = 0 
   ( ) yes = 1 
 
Work status  ( ) don’t work = 0 
   ( ) part time = 1 
   ( ) full time = 2 
   ( ) volunteer = 3 
   ( ) other: _____ = 4 
 
Marital/partner status ( ) single = 0 
   ( ) living with partner = 1 
   ( ) married = 2 
   ( ) separated = 3 
   ( ) divorces = 4 
   ( ) other ________= 5 
 
Housing situation ( ) homeless = 0 
   ( ) shelter = 1 
   ( ) half way =2 
   ( ) apartment = 3 
   ( ) own home = 4 
   ( ) other____ = 5 
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Appendix B (continued) 
 
Length of time with HIV _____________ months 
 
HIV illness stage:  ( ) asymptomatic = 1 
    ( ) symptomatic = 2 
    ( ) AIDS = 3 
 
Antiretroviral therapy  ( ) none now = 0 
    ( ) on treatment = 1 
 
Most recent HIV RNA  _________________ 
DATE:   _________________ 
 
Most recent HCV RNA _________________ 
DATE:    _________________ 
 
HCV subtype   _________________ 
 
Liver biopsy    _________________ 
Date    _________________ 
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Appendix C 
Parent Study Alcohol and Drug Dependency Questionnaire 
I would now like to ask you some questions about alcohol and drug use. 
 
Have you had any problems with alcohol or drugs?    No ( ) 0 
         Yes ( ) 1 
 
IF YES – please complete the following 
 
Substance 0 = No 1 = Yes If yes, when was the 
last time? 
Alcohol   
Heroin   
Speedball (coke & heroin injected)   
Cocaine   
Crack   
Marijuana   
Amphetamines (non-prescription)   
Tranquilizers (non-prescription)   
Street Methadone   
Street Morphine   
Ecstasy   
Oxycontin   
Other   
 
What has been the most problematic substance for you?  __________________ 
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Appendix D 
Parent Study Mental Health Questionnaire 
Have you ever been told that you have any of the following by a 
healthcare provider? 
0 = no 
1 = yes 
8 = don’t know 
Depression  
Anxiety  
Panic Disorder  
Bipolar Disorder (manic / depressive illness)  
Post Traumatic Stress Disorder (PTSD)  
Schizophrenia  
Personality Disorder  
Obsessive/Compulsive Disorder  
Other  
Have you ever been admitted to a hospital to treat depression or 
mood problem? 
0 = no 
1 = yes 
Are you currently taking any medications to treat mental health 
problems? 
0 = no 
1 = yes 
0 = no 
1 = yes Have you ever tried to kill yourself? 
How long ago was this? ___ months 
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Appendix E 
Receipt for Data 
 
Contents of Data Set:  _____________________________________________________ 
 
________________________________________________________________________ 
 
________________________________________________________________________ 
 
Date Received:  __________________________________________________________ 
 
Tapes and number:  _______________________________________________________ 
 
Transcripts and number:  ___________________________________________________ 
 
Notes and number of pages:  ________________________________________________ 
 
Additional Data (list each item):  _____________________________________________ 
 
________________________________________________________________________ 
 
________________________________________________________________________ 
 
________________________________________________________________________ 
 
Investigator of Parent Study:  _______________________________________________ 
 
Signature of Researcher Receiving Data Set:  ___________________________________ 
 
 
Return of Data Set 
 
Date Data Returned to Principal Investigator:  __________________________________ 
 
Verification of Contents upon return:  _________________________________________ 
 
Additional Information:  ___________________________________________________ 
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Appendix F 
Secondary Data Inclusion/Exclusion Extraction Criteria Tool 
Participant #____________ 
Inclusion criteria: 
1. Did the participant have a history of substance abuse: yes/no? 
a. Must be yes to be included in the final sample. 
2. Did the participant talk about substance abuse: yes/no? 
a. Must be yes to be included in the final sample. 
3. Did the patient the participant talk decisions surrounding HCV treatment: yes/no? 
a. If the participant did not talk about these decisions, the interview is not 
automatically excluded. This will be discussed with the dissertation 
chairperson. 
4. Did the participant talk about substance abuse influencing HCV treatment 
decisions: yes/no? 
a. If the participant did not talk about these decisions, the interview is not 
automatically excluded. This will be discussed with the dissertation 
chairperson. 
Does the interview meet the inclusion criteria: yes/no? 
If no, please explain. 
PhD student comments: 
Chairperson comments: 
Second committee member comments: 
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Appendix G 
Secondary Data Extraction Tool 
Participant #:_______________ 
1. Substance Abuse Experience 
 
• Decision Problem 
o Alternative/choices 
o Probability outcomes/consequences 
 
• Contextual Factors 
o Provider interactions 
o Environmental demands 
o Information (education) 
 
• Patient Factors 
o Personal Values 
o Decision Styles 
o Expectations 
o Physical state 
o Physiological state 
 
2. Describe experiences of substance abuse as it relates to HCV decision-making 
treatment: 
 
• Decision Problem 
o Alternative/choices 
o Probability outcomes/consequences 
 
• Contextual Factors 
o Provider interactions 
o Environmental demands 
o Information (education) 
 
• Patient Factors 
o Personal Values 
o Decision Styles 
o Expectations 
o Physical state 
o Physiological state 
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Appendix G (continued) 
3. New and emerging factors not captured by theoretical framework 
 
• Decision Problem 
• Contextual Factors 
• Patient Factors 
• Any other emerging factors 
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